Elephant Herpesvirus: EEHV Reference

Overview, Taxonomy, and Genetic Diversity of Elephant Endotheliotropic Herpesvirus (EEHV)

Overview

Elephant endotheliotropic herpesviruses (EEHVs) constitute a group of highly pathogenic, phylogenetically distinctive viral agents that represent the single most important infectious cause of mortality in juvenile Asian elephants (Elephas maximus) globally, and an emerging and increasingly recognized threat to African elephants (Loxodonta africana) under human care and in free-ranging populations [1, 10, 15, 23]. First identified as a cause of acute hemorrhagic disease in the mid-1990s, EEHV has since been implicated in the deaths of a substantial proportion of captive-born Asian elephant calves in North America, Europe, and Asia, with case fatality rates historically approaching 65–70% in clinically apparent infections [10, 15, 33]. The impact of EEHV on ex situ conservation breeding programs is profound; over the last three decades, the virus has been responsible for more than half of all deaths recorded in Asian elephant calves older than one month of age in European zoos, and it continues to be the leading cause of death for young elephants in North American and European facilities despite the implementation of sensitive molecular diagnostic surveillance and aggressive antiviral therapeutic protocols [5, 15, 34, 38].

The disease syndrome engendered by EEHV infection, EEHV hemorrhagic disease (EEHV-HD), is a catastrophic, multisystemic illness characterized by rapid onset, fulminant progression, and extensive vascular compromise. The hallmark of EEHV-HD is a profound, selective tropism for microvascular endothelial cells, leading to widespread endothelial damage, increased vascular permeability, disseminated intravascular coagulation (DIC), and ultimately multiorgan failure and cardiovascular collapse [4, 9, 30]. Clinically, affected calves present with a constellation of signs that may include lethargy, anorexia, facial and cervical edema, cyanosis and ulceration of the tongue and buccal mucosa, petechial and ecchymotic hemorrhages on mucous membranes and skin, hematuria, hemorrhagic diarrhea, lameness, and signs of colic; death often ensues within 24–72 hours of the onset of overt clinical signs [10, 24, 36, 39]. The pathogenesis of EEHV-HD is now understood to involve not only direct viral cytopathic effects on endothelial cells, including the formation of amphophilic to basophilic intranuclear inclusion bodies and endothelial cell apoptosis and necrosis, but also a secondary host-driven immunopathological component characterized by a dysregulated, excessive proinflammatory cytokine response, or cytokine storm, involving marked elevations of interferon-gamma (IFN-γ), interleukin-6 (IL-6), and interleukin-10 (IL-10) [9, 19, 30]. This systemic inflammatory cascade, in conjunction with endothelial injury, triggers a consumptive coagulopathy with microthrombi formation, thrombocytopenia, hypofibrinogenemia, and elevated D-dimer concentrations, fulfilling the International Society on Thrombosis and Hemostasis (ISTH) criteria for overt DIC [1, 9, 30]. The hematologic hallmarks of incipient EEHV-HD include a precipitous decline in monocyte and lymphocyte counts (monocytopenia and lymphocytopenia), followed by thrombocytopenia, and the presence of toxic heterophil changes; these alterations often precede detectable viremia or overt clinical signs, making complete blood count (CBC) analysis an indispensable tool for early intervention [2, 3, 10, 43, 46].

EEHV infections are not invariably fatal; indeed, the natural history of these viruses is characterized by ubiquitous, lifelong, latent infection in adult elephants, with periodic, typically asymptomatic shedding of virus from mucosal surfaces, particularly via trunk secretions and saliva [8, 11, 38, 41]. The overwhelming majority of adult elephants in both captive and range-country settings are seropositive for one or more EEHV species, indicating near-universal exposure and the establishment of latency [26, 32, 38]. Fatal hemorrhagic disease is overwhelmingly a disease of juvenile elephants, typically between one and eight years of age, and accumulating evidence indicates that lethal outcomes are associated with primary infection occurring in the face of waning maternally derived antibody levels, rather than with reactivation of latent virus [25, 31, 40]. This paradigm has profound implications for understanding the epidemiology of EEHV-HD and for the rational design of vaccination and management strategies aimed at protecting at-risk calves.

Taxonomy

The taxonomy of EEHVs has been a subject of considerable scientific interest and periodic revision since their initial discovery. These viruses are formally classified within the family Herpesviridae, order Herpesvirales [6, 15]. However, they occupy a highly distinctive and evolutionarily isolated position within the family. Molecular phylogenetic analyses, based on comparisons of conserved core genes such as the DNA polymerase (U38) and terminase (U89) genes, have consistently demonstrated that EEHVs are only distantly related to the three classical subfamilies of mammalian herpesviruses, Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae [15, 38, 45]. Instead, EEHVs are proposed to represent a novel, fourth subfamily of mammalian herpesviruses, provisionally designated Deltaherpesvirinae, which also includes the Proboscivirus genus [42, 45]. This classification is supported by the unique genomic architecture and biological properties of EEHVs, including their distinctive tropism for endothelial cells, their inability to be propagated in conventional cell culture systems, and their phylogenetic clustering with herpesviruses of other Afrotherian species, such as the Florida manatee (Trichechatus manatus latirostris) and the hyrax [44, 45].

Within the EEHV group, seven distinct viral species, designated EEHV1 through EEHV7, have been formally recognized and characterized to date [15, 18, 25]. These species are further subdivided into multiple subspecies, reflecting finer-scale genetic diversity within each species [25, 42]. The classification is grounded in genetic divergence, particularly within the viral glycoprotein B (gB), glycoprotein H (gH), and glycoprotein L (gL) genes, as well as in the viral G protein-coupled receptor (vGPCR) and other genomic regions [25, 35].

EEHV1 is by far the most prevalent, most extensively studied, and most clinically significant species, particularly with respect to disease in Asian elephants. EEHV1 is itself composed of two principal chimeric subspecies, EEHV1A and EEHV1B, which differ in their genomic composition, geographic distribution, and possibly in their pathogenicity [10, 22, 27, 42]. EEHV1A is the most commonly identified causative agent of fatal EEHV-HD worldwide, having been documented in lethal cases across North America, Europe, India, Thailand, Myanmar, Malaysia, Indonesia (Sumatra), and other range countries [10, 24, 33, 35, 39, 42]. EEHV1B is less frequently encountered but has also been associated with fatal disease, as well as with subclinical and clinical infections [10, 27, 43].

EEHV4 is the second most prevalent cause of EEHV-HD in Asian elephants, particularly in Thailand and other parts of Southeast Asia, and has been documented both as a sole pathogen and in co-infection with EEHV1A [10, 21, 28, 47, 48]. While the case fatality rate for EEHV4 is generally lower (approximately 40%) compared to EEHV1A (75%) or EEHV1B (83%), EEHV4 can still cause severe, acute hemorrhagic disease, particularly with gastrointestinal and cardiovascular involvement [10, 21].

EEHV5 was initially identified as a cause of clinical and subclinical infections in captive Asian elephants in the United States and has subsequently been recognized as a significant pathogen capable of causing fatal hemorrhagic disease in Asian elephants in Europe and elsewhere [22, 27, 37]. The first death of an Asian elephant attributable to EEHV5 Germany was reported in 2024, with whole-genome sequencing revealing substantial genetic divergence (3,881 variants) from the previously published EEHV5 reference genome, highlighting the ongoing evolution and diversification of this species [22].

EEHV2, EEHV3, EEHV6, and EEHV7 are predominantly associated with African elephants. EEHV2 has been recognized as a cause of fatal and non-fatal clinical disease in African elephants under human care in North America, with recent case series documenting lethal infections in calves and subadults [7, 13]. EEHV3, particularly the subtype EEHV3A, has emerged as a significant cause of acute hemorrhagic disease in African elephants in North American zoos, with outbreaks characterized by rapid progression and high mortality in seronegative individuals [29, 31]. EEHV6 has been identified in a fatal case of hemorrhagic disease in a two-year-old African elephant in Austria, underscoring the pathogenic potential of this species [17]. EEHV7 (including the subtype EEHV7A) was initially detected only in benign pulmonary and skin nodules and in trunk secretions of African elephants, but recent reports have documented clinical disease, including leukopenia, lymphopenia, monocytopenia, and thrombocytopenia, associated with EEHV7A viremia in subadult African elephants [7, 20].

Genetic Diversity

The genetic diversity of EEHVs is a defining feature of this viral group and has major implications for pathogenesis, host range, diagnostic assay design, and vaccine development. The EEHV genome is large, comprising approximately 180 kilobase pairs (kbp) and encoding over 115 open reading frames (ORFs) [14, 16, 42]. The genome organization is complex, with significant variation in gene content, particularly in the terminal repeats and in regions encoding tegument proteins and glycoproteins, which are key determinants of host immune recognition and viral entry [42].

Within EEHV1, the genetic diversity is particularly well-characterized, owing to the availability of numerous partial and complete genome sequences from geographically disparate cases. EEHV1A and EEHV1B are chimeric variants, meaning they appear to have arisen from recombination events between ancestral EEHV1 lineages [10, 42]. Partial genome sequencing, particularly of the vGPCR (U51) locus, the DNA polymerase (U38) gene, and the terminase (U89) gene, has revealed multiple subtypes within EEHV1A. For example, analysis of the vGPCR locus has identified distinct subtypes, with the D2 subtype documented in confirmed fatal cases from Sumatran elephants (Elephas maximus sumatranus) that differed from all previously characterized EEHV1A strains [35]. Similarly, sequencing of over 5,610 base pairs from fatal cases in Myanmar logging camps revealed major genetic differences among strains and from all previously characterized EEHV1A strains, demonstrating the existence of geographically distinct lineages [39]. In contrast, studies in India and Thailand have shown that many EEHV1A isolates share 99.9% or greater sequence identity in the POL1 (U38) and terminase genes, suggesting a relatively conserved backbone with localized hotspots of variation [24]. Overall, sequence identity among EEHV1A strains for core genes such as DNA polymerase, gB, and gL is estimated at approximately 99%, indicating strong purifying selection on these functionally essential proteins [14, 16].

The genetic diversity of EEHV1 is not merely a taxonomic curiosity; it has direct clinical relevance. The two principal subtypes, EEHV1A and EEHV1B, exhibit differences in disease severity and prevalence. In a large retrospective analysis of 103 confirmed EEHV cases in Thailand, EEHV1A was the most prevalent subtype, accounting for 58% of cases, followed by EEHV4 at 34%, and EEHV1B at 5.8% [10]. The case fatality rate was highest for EEHV1B (83%), followed by EEHV1A (75%), and lowest for EEHV4 (40%) [10]. Co-infections with EEHV1A and EEHV4 were observed in 1.9% of cases and were uniformly fatal (100% case fatality rate) [10], a finding corroborated by other reports of severe, rapidly fatal EEHV1/4 co-infections in Asian elephant calves in Europe and Asia [21, 48]. The mechanisms underlying the apparent increased virulence of co-infections remain unclear but may involve synergistic interactions between viral species, such as enhanced replication or immune modulation.

For the African elephant-associated EEHVs, genetic diversity is also being increasingly documented. EEHV3 has been shown to comprise at least two subtypes, EEHV3A and EEHV3B, based on sequence analysis of gB and other genes [29, 31]. The serological and genetic distinction between these subtypes is sufficient to affect cross-protective immunity; African elephants that succumbed to EEHV3-HD were seronegative for EEHV3 prior to infection, whereas survivors and adult herdmates were seropositive [31]. Whole-genome sequencing of EEHV5 from a fatal case in Germany identified 3,881 single nucleotide variants (SNVs) distributed across the entire genome relative to the reference sequence, underscoring the rapid evolution of this species and the potential for the emergence of novel pathogenic variants [22].

The genetic diversity of EEHVs also presents challenges for diagnosis and surveillance. Most quantitative PCR (qPCR) assays target conserved regions of the DNA polymerase or terminase genes to achieve broad detection across multiple EEHV species, but the existence of sequence variation necessitates the use of degenerate primers or multiple species-specific probes to ensure comprehensive coverage [12, 18, 27]. The development of serological assays, such as the luciferase immunoprecipitation system (LIPS) and enzyme-linked immunosorbent assays (ELISAs) targeting gB and gH/gL, has been complicated by the cross-reactivity of gB-specific antibodies across EEHV species, whereas gH/gL-based assays offer superior species-specific discrimination [25, 38, 40]. The ability to distinguish between infections with different EEHV species and to identify seronegative, at-risk juveniles is critical for the clinical management of captive elephant herds and for understanding the epidemiology of EEHV in wild populations [25, 31, 40].

In summary, the EEHVs represent a genetically diverse, evolutionarily unique group of herpesviruses that are universally prevalent in adult elephants but cause devastating, often fatal hemorrhagic disease in juvenile animals. The taxonomy of these viruses, encompassing seven species and numerous subspecies (EEHV1A, EEHV1B, EEHV2 through EEHV7, with subtypes such as EEHV3A, EEHV3B, and EEHV7A), reflects a complex evolutionary history shaped by chimerism, recombination, and host adaptation. The considerable genetic diversity within and between EEHV species has profound implications for viral pathogenesis, host immunity, diagnostic accuracy, and the eventual development of broadly protective vaccines.

Molecular Pathogenesis of EEHV: Viral Entry, Replication, and Endotheliotropism

The molecular pathogenesis of elephant endotheliotropic herpesvirus (EEHV) represents a remarkable and devastating example of viral adaptation to a highly specific cellular niche within a unique evolutionary host. Despite belonging to a proposed novel subfamily of mammalian herpesviruses, the Deltaherpesvirinae, EEHV has evolved a sophisticated molecular machinery that permits exquisitely targeted infection of endothelial cells, culminating in a pathognomonic hemorrhagic syndrome that has decimated juvenile elephant populations globally [4, 30]. Understanding the precise molecular mechanisms governing viral entry, replication, and the basis for this profound endotheliotropism is essential for rational vaccine design, therapeutic intervention, and the development of predictive biomarkers for disease progression.

Molecular Basis of Viral Entry: Glycoprotein-Mediated Fusion and Cellular Receptor Engagement

The initial steps of EEHV infection are orchestrated by a conserved suite of envelope glycoproteins that constitute the core entry machinery for herpesviruses. Genomic and functional analyses have identified glycoprotein B (gB), gH, gL, and gO as the critical mediators of viral attachment and membrane fusion [5, 42, 49]. gB, the most highly conserved herpesvirus glycoprotein, serves as the primary fusogen, catalyzing the merger of the viral envelope with the host cell membrane. Crucially, EEHV1A gB possesses a conserved furin cleavage site (Arg-X-Lys/Arg-Arg) at residue 472, which is essential for the proteolytic activation of the fusogenic capacity of the molecule [42]. This cleavage, mediated by cellular furin or furin-like proprotein convertases, generates the mature, fusion-competent form of gB, a processing step that is conserved across the Herpesviridae and is absolutely required for infectivity. The subsequent conformational changes that drive membrane merger are thought to be triggered by the regulatory complex formed by gH and gL, which in turn may be modulated by gO, a component hypothesized to be involved in receptor recognition and cell-type specificity [5].

The precise cellular receptor(s) exploited by EEHV on elephant endothelial cells remain incompletely characterized, representing a significant gap in our molecular understanding of this disease. However, compelling evidence points to a highly restricted receptor distribution that fundamentally underlies the virus's tropism. Studies employing in situ hybridization with RNAscope probes targeting the EEHV1A DNA polymerase and terminase genes have unequivocally demonstrated that positive hybridization signal is exclusively confined to endothelial cell nuclei in all tissues examined from fatal EEHV-HD cases [4, 24, 54]. No signal was detected in epithelial cells, leukocytes, or mesenchymal cells other than endothelial cells, indicating that the molecular determinants for viral entry are either uniquely expressed or functionally accessible only on the surface of capillary endothelium [4, 54]. This exquisite cellular restriction suggests that the receptor(s) utilized by EEHV, whether a specific integrin heterodimer, a heparan sulfate proteoglycan variant, or a yet-unidentified protein, is a defining feature of the elephant endothelial cell surface. The observed variation in tissue tropism, with the heart and liver harboring the most abundant viral signal, while the kidney and brain exhibit minimal to no detectable signal, is likely a direct consequence of endothelial cell heterogeneity across different vascular beds [4, 24]. Differential expression patterns of the cognate entry receptor, or differences in the local micro-environmental factors that modulate receptor accessibility or post-entry restriction factors, probably dictate which capillary beds are most permissive to infection.

Replication Strategy and Subcellular Sites of Viral Propagation

Following entry, the viral capsid is trafficked to the nuclear pore, where the linear double-stranded DNA genome is released into the nucleoplasm. EEHV genomes are large, approximately 180 kb in size, and encode over 115 open reading frames, including a full complement of replication-associated enzymes and structural proteins [14, 16, 42]. The replication cycle follows the canonical herpesvirus paradigm, with immediate-early, early, and late phases of gene expression. The viral DNA polymerase, encoded by the U38 gene, is the core enzyme responsible for genome replication and is a primary target for antiviral therapy and diagnostic detection [12, 16, 50, 51, 56]. Immunohistochemical detection of the EEHV DNA polymerase nonstructural protein has been used extensively to map sites of active viral replication in vivo. Consistent with the in situ hybridization data, the DNA polymerase antigen is predominantly detected within the nuclei of endothelial cells lining capillaries throughout the viscera of fatal cases, confirming that these cells are the primary site of productive viral replication [24, 51]. The terminase gene, encoding a protein complex essential for packaging newly replicated genomic DNA into procapsids, also shows robust and specific hybridization signal exclusively in endothelial cell nuclei, reinforcing this conclusion [4, 54].

Interestingly, a broader cellular tropism has been identified when examining not just acute fatal cases but also persistent or subclinical infections. In addition to endothelial cells, EEHV DNA polymerase antigens have been detected in the epithelial cells of the alimentary tract, salivary glands, and in monocytic lineage cells [11, 51]. Viral particles have been observed within the cytoplasm of monocytes from persistently infected elephants, and monocytic cells have been demonstrated to harbor viral DNA [11, 51, 53]. These observations support a dual-pathogenesis model: during acute, fatal hemorrhagic disease, the virus exhibits a strict and devastating endotheliotropic replication strategy; however, during persistent or latent infection, the virus may utilize epithelial cells for shedding and replication, while monocytes/macrophages may serve as vehicles for viral dissemination or as reservoirs for latency [11, 53]. The in vitro isolation of EEHV has proven notoriously challenging, with only limited and abortive replication observed in the human myeloid leukemia cell line U937, which is itself of monocytic origin [42, 52]. This abortive replication, characterized by the detection of early viral antigens but a rapid decline in viral genome copies upon passage, underscores the stringent species-specific and cell-type-specific requirements for complete viral replication. The inability to propagate EEHV in conventional cell culture systems remains a major bottleneck for detailed mechanistic studies of the replication cycle [14, 15].

Endotheliotropism: The Molecular Determinants of Vascular Targeting and Tissue Damage

The molecular basis for the profound endotheliotropism of EEHV is the central question in understanding the pathogenesis of hemorrhagic disease. The exclusive detection of viral nucleic acids and antigens in endothelial cell nuclei during acute fatal infection strongly suggests that the block to infection in other cell types occurs at an early, post-entry stage, possibly at the level of receptor engagement or intracellular trafficking [4, 51, 54]. It is plausible that the gB-gH-gL-gO fusion machinery is specifically adapted to engage a receptor or co-receptor complex that is uniquely expressed on elephant endothelial cells [5, 42]. The lack of detectable infection in other cell types despite their apparent susceptibility in other contexts (e.g., epithelial cells in persistent infections) indicates a dramatic shift in the viral life cycle or a difference in the host immune state that restricts replication to the endothelium during the acute phase.

Once infection is established within the capillary endothelium, the resulting damage is catastrophic and leads to a stereotyped cascade of pathophysiological events. The direct viral cytopathic effect, evident as endothelial cell swelling, apoptosis, and the formation of amphophilic to basophilic intranuclear inclusion bodies, compromises the integrity of the vascular lining [24, 30]. This endothelial injury exposes the subendothelial basement membrane, triggering platelet adhesion, aggregation, and activation. Immunohistochemical analysis has revealed a significant upregulation of platelet endothelial cell adhesion molecule-1 (PECAM-1) and von Willebrand factor (vWF) in injured blood vessels, markers of endothelial activation and procoagulant shift [9]. The consequence is the widespread formation of microthrombi, which were observed in 63% of EEHV-HD cases in a large retrospective European study, involving the vasculature of the tongue, heart, lung, liver, kidney, and brain [9, 24, 30]. This disseminated microvascular thrombosis, combined with the profound consumption of platelets (thrombocytopenia is a hallmark clinical feature), fibrinogen, and clotting factors, culminates in overt disseminated intravascular coagulation (DIC) [1, 9, 30]. The ensuing consumptive coagulopathy depletes hemostatic reserves, leading to the severe, multifocal hemorrhages that characterize the disease.

The tissue damage is further amplified by a dysregulated host immune response. Infiltration of Iba-1-positive macrophages is markedly increased in inflamed tissues, and there is a concomitant upregulation of pro-inflammatory cytokine mRNA [9, 53]. Specifically, elevated levels of interleukin-6 (IL-6), interleukin-10 (IL-10), and interferon-gamma (IFN-γ) have been detected in the blood and tissues with high viral loads (heart and liver) of fatal EEHV-HD cases [19]. This cytokine profile is characteristic of a cytokine storm syndrome, an excessive and uncontrolled inflammatory response that contributes to multi-organ dysfunction and cardiovascular collapse [19, 30]. The release of cardiac troponin I (cTnI) into the circulation, which correlates strongly with the presence and severity of clinical disease, provides direct evidence of myocardial damage from this combined ischemic and inflammatory insult [55]. Therefore, the molecular pathogenesis of EEHV-HD is a two-pronged assault: a direct, lytic infection of capillary endothelial cells that triggers a catastrophic hemostatic failure (DIC), compounded by a secondary, maladaptive cytokine storm that drives systemic inflammation and organ failure. The emergence of EEHV from a state of latency in adult elephants, often precipitated by stressors such as social disruption or translocation, involves a reactivation of this same pathogenic program in a susceptible, immunologically naïve juvenile [8, 15].

Epidemiology of EEHV: Host Range, Geographic Distribution, and Risk Factors

The epidemiology of elephant endotheliotropic herpesvirus (EEHV) represents a complex and rapidly evolving field of study, characterized by a ubiquitous viral presence across both Asian (Elephas maximus) and African (Loxodonta africana) elephant populations, yet a highly selective and often fatal disease manifestation primarily in juvenile animals. Understanding the intricate interplay between host species, viral genotype, geographic location, and a multitude of biological and environmental risk factors is paramount for developing effective conservation strategies and clinical management protocols for this devastating pathogen. The virus, a member of the proposed Deltaherpesvirinae subfamily, has co-evolved with elephants for millions of years, establishing a delicate equilibrium that is tragically disrupted in a subset of young, immunologically naive individuals [26, 38].

Host Range and Species Susceptibility

The host range of EEHV is principally restricted to elephants of the family Elephantidae, encompassing both extant genera: Elephas (Asian elephants) and Loxodonta (African elephants). However, the susceptibility to clinical disease and the specific viral genotypes involved differ markedly between these two host species. For decades, EEHV hemorrhagic disease (EEHV-HD) was considered a disease predominantly of Asian elephants, with the vast majority of fatalities documented in this species [15, 23]. The virus is now recognized as the leading cause of mortality in juvenile Asian elephants under human care in North America, Europe, and Asia, and it is increasingly documented as a significant cause of morbidity and mortality in free-ranging populations as well [5, 10, 33, 35, 39].

Historically, African elephants were thought to be less susceptible to clinical EEHV-HD, with infections often being subclinical or resulting in mild, self-limiting illness [7, 58]. This paradigm has shifted dramatically in recent years, with a surge in documented clinical cases and fatalities in African elephants, particularly in North American zoological institutions. A landmark case series documented five sequential EEHV3A infections in African elephants at a single institution, resulting in two fatalities, thereby establishing EEHV3 as a significant pathogen in this species [29]. Subsequent reports have confirmed clinical disease and death due to EEHV2, EEHV6, and EEHV7A in African elephants, underscoring the broadening threat [13, 17, 20]. The first detection of clinical disease due to EEHV7A in two subadult African elephants, which previously had only been associated with benign nodules, further highlights the expanding pathogenic potential of these viruses [20]. A critical epidemiological observation is that fatal EEHV-HD in both Asian and African elephants is strongly associated with primary infection in seronegative individuals, rather than reactivation of latent virus [31, 40]. This was elegantly demonstrated in a study of African elephants, where those succumbing to EEHV3-HD were seronegative for EEHV3 prior to infection, while those surviving were seropositive, indicating prior exposure and immunological memory [31]. Similarly, in Asian elephants, fatal EEHV1-HD cases are consistently linked to low or undetectable levels of species-specific antibodies, particularly against the gH/gL glycoprotein complex [25, 38, 40]. This suggests that the immune status of the calf, rather than inherent species resistance, is the primary determinant of disease outcome.

Geographic Distribution and Viral Genotypes

EEHV has a truly global distribution, mirroring the range of its elephant hosts, both in situ and ex situ. The virus is endemic in captive elephant populations across North America, Europe, and Asia, and has been molecularly confirmed in free-ranging populations across Asia and Africa [7, 10, 24, 27, 32, 33, 35, 39]. The geographic distribution of specific viral genotypes, however, reveals a complex and dynamic picture.

EEHV1 (subtypes 1A and 1B) is the most prevalent and most frequently lethal genotype in Asian elephants worldwide. It has been identified as the causative agent in fatal cases across North America, Europe, India, Thailand, Myanmar, Malaysia, and Indonesia [10, 24, 33, 35, 36, 39, 42]. In a large retrospective study of 103 EEHV cases in Thailand, EEHV1A accounted for 58% of cases, with a case fatality rate of 75%, while EEHV1B was less common (5.8%) but more lethal (83% fatality) [10]. EEHV1A has also been detected in African elephants, though it is not the predominant cause of disease in this species [7]. The genetic diversity within EEHV1 is substantial; for instance, strains from Myanmar and Sumatra have shown major genetic differences from previously characterized strains, suggesting the existence of geographically distinct lineages [35, 39].

EEHV4 is the second most prevalent genotype in Asian elephants, particularly in Thailand, where it was responsible for 34% of cases in one study [10]. Intriguingly, EEHV4 appears to be less virulent than EEHV1, with a case fatality rate of 40% [10]. It has been detected in both captive and wild Asian elephants in China and Thailand [27, 47]. Co-infections of EEHV1A and EEHV4 have been documented and are associated with a universally fatal outcome (100% case fatality rate in one study), suggesting a synergistic or additive pathogenic effect [10, 21, 48].

EEHV5 is a more recently recognized genotype that has been associated with both clinical and subclinical infections in Asian elephants [37]. While often causing mild or asymptomatic infections, fatal EEHV5-HD has been reported, including the first documented death in Germany, which was linked to a genetically distinct strain [22, 37]. EEHV5 has also been detected in captive elephants in China and Malaysia [27, 64].

African elephant-specific genotypes (EEHV2, EEHV3, EEHV6, EEHV7) are increasingly recognized as significant pathogens. EEHV3 has caused multiple fatal outbreaks in North American zoos [29, 31]. EEHV2 has been documented in fatal cases across multiple North American institutions, with a key finding that fatal cases were seronegative for EEHV2, while survivors were seropositive [13]. EEHV6 was responsible for a fatal case in a two-year-old African elephant in Austria, followed by a non-fatal case in a herdmate, demonstrating within-herd transmission [17]. EEHV7A, previously considered benign, has now been linked to clinical disease with significant hematologic changes in subadult African elephants [20]. The detection of EEHV2 and EEHV3-4-7 in apparently healthy free-ranging African elephants in Kruger National Park, South Africa, confirms that these viruses circulate asymptomatically in wild populations, serving as a reservoir for potential transmission to naive individuals [7].

Risk Factors for Infection and Disease Progression

The transition from ubiquitous, asymptomatic infection to fatal hemorrhagic disease is governed by a complex interplay of host, viral, and environmental risk factors.

Age and Immunological Naivety: Age is the most critical host risk factor. EEHV-HD is overwhelmingly a disease of juvenile elephants, typically between 1 and 10 years of age, with the highest risk group being calves 2–4 years old [10, 34]. This age predilection is directly linked to the waning of maternally derived antibodies. Calves are born with high levels of passively acquired anti-EEHV antibodies, which provide protection during the first year of life [26, 31, 40]. As these maternal antibodies decline, typically between 1 and 4 years of age, a window of susceptibility opens [26, 40]. If a calf encounters a high dose of a specific EEHV genotype during this period without sufficient neutralizing antibodies, it may fail to control the primary infection, leading to uncontrolled viral replication and fulminant disease [25, 40]. Studies have shown that young elephants in large, multi-generational herds in range countries (e.g., Sri Lanka) maintain high antibody levels due to frequent, low-dose re-exposure from shedding adults, whereas calves in smaller European zoo herds experience a significant drop in antibody levels, correlating with a higher incidence of fatal disease [26].

Serostatus and Antibody Levels: The level of pre-existing, genotype-specific antibodies is the single most important predictor of disease outcome. Multiple studies have conclusively demonstrated that elephants with low or undetectable antibodies against the specific EEHV (sub)species they encounter are at extreme risk of developing fatal EEHV-HD [25, 31, 40]. The development of (sub)species-specific serological assays, particularly those targeting the gH/gL glycoprotein complex, has been a major breakthrough. Unlike the highly cross-reactive gB antibodies, gH/gL antibodies are largely type-specific and can accurately identify which elephants are at risk for which specific viral genotype [25]. For example, a fatal case of EEHV5 in a Japanese zoo was preceded by a decline in antibody levels to undetectable levels [59]. This paradigm holds true for both Asian and African elephants, where fatal EEHV3 infections occurred only in seronegative individuals [31].

Social and Environmental Stressors: Stress is widely hypothesized to be a trigger for viral reactivation in latently infected adults and may increase susceptibility in juveniles. Management-related social changes, such as between-herd and within-herd movements, have been quantitatively linked to increased odds of EEHV shedding. A study on captive Asian elephants found that within-herd movements (e.g., introducing a new bull for mating) posed the most significant risk, increasing the odds of viral recrudescence by nearly seven-fold (OR = 6.86) [8]. This suggests that social disruption can reactivate latent virus in adult shedders, increasing the environmental viral load and exposing naive calves. Furthermore, a longitudinal study of a calf that succumbed to EEHV-HD noted a decrease in stress biomarkers (salivary cortisol, fecal glucocorticoid metabolites) in the 12 days preceding viremia, which is paradoxical but may reflect a state of adrenal exhaustion or immunosuppression [2]. Seasonal variations also play a role; in Thailand, EEHV detection rates are significantly higher in the summer, potentially due to heat stress, reduced food quality, and increased oxidative stress [41, 60]. Elevated oxidative stress markers, such as reactive oxygen species (ROS) and malondialdehyde (MDA), have been associated with EEHV shedding events, suggesting that cellular damage may facilitate viral replication [60].

Herd Management and Transmission Dynamics: The management structure of captive elephant herds profoundly influences transmission dynamics. Large herd sizes, as seen in some range country facilities, promote frequent, low-level exposure, boosting immunity in young animals [26]. Conversely, small, isolated zoo herds may have a different transmission dynamic, where a single shedding event can expose a naive calf to a high viral dose. The primary route of transmission is thought to be via direct contact with infectious secretions, particularly trunk secretions (trunk washes), saliva, and feces [11, 62, 63]. Trunk washes are the most sensitive non-invasive sample for detecting shedding, outperforming oral swabs [57]. Fecal shedding has been documented, offering a non-invasive tool for surveillance in free-ranging populations [62, 63]. The index case in a herd is often an adult elephant undergoing a stress-related reactivation event, which then sheds virus and infects susceptible calves [37, 58]. The presence of asymptomatic shedders is a critical feature of EEHV epidemiology; studies using serological assays have revealed that a significant proportion of apparently healthy adult elephants are actively shedding virus, acting as a constant source of infection for the herd [32, 50].

Genetic and Hereditary Factors: There is emerging evidence that genetic or hereditary factors may influence susceptibility to EEHV-HD. A retrospective study of the European captive Asian elephant population found that specific sires and dams were associated with a three-fold or higher risk of their calves developing EEHV-HD, even after accounting for zoo-associated factors [34]. This suggests a potential heritable component to disease susceptibility, possibly related to immune response genes (e.g., MHC haplotype). However, the study also found that specific zoos were significant risk factors, indicating that management practices and environmental conditions are at least as important as genetics [34].

Viral Genotype and Co-infections: The specific viral genotype involved is a major determinant of disease severity. As noted, EEHV1A and EEHV1B are associated with high case fatality rates (75% and 83%, respectively), while EEHV4 is less lethal (40%) [10]. Co-infections, particularly EEHV1A and EEHV4, are uniformly fatal, likely due to a compounded cytopathic effect on the vascular endothelium [10, 21, 48]. The viral load, or level of viremia, is also a critical prognostic indicator. High viremia (≥20,000 viral genome equivalents/mL) is strongly associated with clinical disease, cardiac damage (elevated cardiac troponin I), and a poor prognosis [55, 61]. The pathogenesis of fatal disease involves a direct cytopathic effect on capillary endothelial cells, leading to widespread vascular damage, disseminated intravascular coagulation (DIC), and a cytokine storm characterized by elevated IL-6, IL-10, and IFN-γ [4, 9, 19, 30].

Clinical Manifestations and Pathophysiology of EEHV Hemorrhagic Disease (EEHV-HD)

Clinical Progression and Diagnostic Hematology

The clinical trajectory of elephant endotheliotropic herpesvirus hemorrhagic disease (EEHV-HD) is notoriously rapid and devastating, with affected calves often progressing from apparent health to death within 12 to 72 hours of the first observable signs [10, 33, 36]. The clinical syndrome is characterized by a constellation of signs that reflect widespread vascular compromise and systemic inflammation. Early indicators are subtle and nonspecific, including lethargy, depression, decreased appetite, and altered behavior patterns [13, 36, 46]. As the disease advances, more alarming signs emerge: facial and neck edema, cyanosis of the tongue and buccal mucosa, multifocal petechial and ecchymotic hemorrhages on mucous membranes, hematuria, diarrhea, and signs of colic [10, 24, 29, 36]. Lameness, trunk discharge, erratic behavior, and recumbence are frequently observed in the terminal stages [36]. The period of illness is remarkably brief, typically lasting between 24 and 42 hours before death ensues in fatal cases [33, 36].

The constellation of hematologic changes that accompany EEHV-HD is both diagnostically critical and pathophysiologically illuminating. The hallmark hematologic finding is a profound and progressive thrombocytopenia, which is consistently reported across all genotypes and species [1, 2, 10, 30, 36, 43]. Platelet counts decline precipitously as the disease progresses, with a dramatic drop often observed immediately prior to death [46]. This thrombocytopenia is a key component of the disseminated intravascular coagulation (DIC)-like syndrome that characterizes the terminal phase of EEHV-HD [1, 30]. Concurrently, infected elephants exhibit leukopenia characterized by a depletion of lymphocytes, monocytes, and heterophils [10, 13, 43]. A particularly sensitive and early indicator is monocytopenia, which can precede the detection of viremia itself [3, 43, 46]. The monocyte:heterophil (M:H) ratio has been identified as a valuable prognostic tool; severely affected elephants demonstrate a ratio lower than 2.37, which is associated with poor outcomes [10]. The presence of immature band heterophils (a "left shift") and severe heterophil toxicity further corroborate the systemic inflammatory response [10, 13, 66]. Interestingly, while these profound hematologic derangements are evident in clinical cases, they often remain within population-derived reference intervals, highlighting the critical utility of individual baseline values and reference change values for accurate interpretation [3].

The severity of clinical signs and the case fatality rate vary significantly among EEHV subtypes. A large retrospective analysis of 103 cases in Thailand revealed that EEHV1A was the most prevalent (58%), with a case fatality rate of 75% [10]. EEHV4 was the second most common (34%), but carried a lower fatality rate of 40% [10]. EEHV1B was associated with an 83% fatality rate, while co-infections with EEHV1 and EEHV4 were universally fatal (100%) [10, 21, 48]. Calves between 2 and 4 years of age constitute the highest risk demographic, and a higher number of cases are observed during the rainy season [10]. No significant gender predilection has been demonstrated [10]. Critically, serostatus is a major determinant of outcome; elephants that are seronegative for the infecting EEHV species at the time of exposure are at the highest risk of developing fatal primary infection [13, 31, 40]. Waning maternal antibody levels, typically occurring between 1 and 4 years of age in European zoo calves, create a window of vulnerability [26, 40]. In contrast, calves in large herds with continuous exposure maintain higher antibody titers and are less likely to succumb [26]. A novel serological assay targeting species-specific gH/gL proteins has proven more predictive of risk than the cross-reactive gB-based assays, as low or undetectable gH/gL antibodies against the specific causative subtype are consistently found in fatal cases [25].

Vascular Pathophysiology and the Role of Disseminated Intravascular Coagulation

The central pathophysiologic event in EEHV-HD is the selective infection and destruction of vascular endothelial cells. Rigorous in situ hybridization (ISH) and immunohistochemical (IHC) studies using RNAscope and anti-EEHV antibodies have conclusively demonstrated that the viral target is exclusively the endothelial cell nucleus [4, 24, 54]. In a landmark study of 12 Asian elephants that died of EEHV1A-HD, positive hybridization signal for viral terminase and DNA polymerase genes was restricted to endothelial cell nuclei in all tissues examined, with no signal detected in epithelial cells, leukocytes, or mesenchymal cells [4]. The heart and liver consistently exhibited the most abundant viral signal, followed by the tongue, lymph node, and spleen [4, 54]. This endothelial tropism is the direct cause of the widespread vascular damage that defines the disease. Histologic examination reveals disseminated vascular necrosis, swelling and apoptosis of endothelial cells, and the presence of amphophilic to basophilic intranuclear inclusion bodies within the endothelium of small blood vessels [9, 24, 30].

The destruction of endothelial integrity triggers a cascade of downstream events culminating in the clinical signs of hemorrhage and edema. Damage to the endothelium exposes the highly thrombogenic subendothelial matrix, leading to the activation of the coagulation cascade. This is evidenced by the formation of microthrombi, which have been observed in 63% of EEHV-HD cases across multiple organs, including the lungs, heart, and brain [30]. The systemic activation of coagulation, coupled with the consumption of platelets and clotting factors, results in an overt disseminated intravascular coagulation (DIC) syndrome [1, 9, 30]. The International Society on Thrombosis and Hemostasis (ISTH) overt DIC scoring system, which incorporates platelet count, fibrinogen concentration, and D-dimer concentration, has been applied to juvenile elephants, and reference intervals have been established for these analytes [1]. In clinical cases, a marked increase in D-dimer concentration and a decrease in plasminogen activity are observed, further confirming the consumptive coagulopathy and secondary hyperfibrinolysis [65]. The resulting hemostatic failure explains the profound hemorrhagic lesions observed postmortem, which include extensive petechiae and ecchymoses on the heart, liver, spleen, gastrointestinal tract, and urogenital tract, as well as widespread edema and ascites [24, 29].

The cataclysmic vascular damage has direct consequences for organ function. The heart is a primary target, as evidenced by the consistent detection of high viral loads and severe hemorrhage in the myocardium [4, 24]. Serum cardiac troponin I (cTnI), a highly specific biomarker of cardiomyocyte injury, is significantly elevated in elephants with high-grade viremia (≥20,000 vge/mL) and is strongly associated with the presence of clinical signs [55]. In fact, the presence of detectable cTnI can help distinguish clinical EEHV-HD from subclinical viremia, and serial measurements show a trend of elevation with disease progression [55]. Death in EEHV-HD is often attributed to acute myocardial hemorrhage and subsequent cardiac failure, superimposed on multiorgan dysfunction from systemic shock [30]. The kidneys, liver, and brain are also severely affected, with congestion, hemorrhage, and vascular thrombosis observed in these organs [24, 30].

Immunopathogenesis: Cytokine Storm and Inflammatory Dysregulation

While the direct cytopathic effect of EEHV on endothelial cells initiates the pathology, it is increasingly clear that a dysregulated host immune response, specifically a cytokine storm, is the primary driver of the severe systemic inflammation and multiorgan failure. Early work demonstrated that the expression of pro-inflammatory cytokine mRNA, including tumor necrosis factor-alpha (TNF-α), is significantly up-regulated in EEHV-HD cases compared to healthy controls [9]. A more comprehensive and recent study comparing mRNA levels of eight different cytokines in blood and tissues from 11 EEHV-HD cases and 12 controls provided compelling evidence for this hypothesis [19]. Significantly elevated mRNA levels of interferon-gamma (IFN-γ), interleukin-6 (IL-6), and interleukin-10 (IL-10) were detected in the blood and in tissues with high viral loads (heart and liver) of fatal cases [19]. These three cytokines are hallmark components of a cytokine storm, and their presence in the context of acute systemic inflammation and multiple organ dysfunction strongly suggests that a pathogen-induced cytokine release syndrome is the final common pathway to death [19].

Importantly, this cytokine induction was not observed in tissues with lower viral loads, such as the tongue, lung, or kidney, indicating that the cytokine storm is spatially and causally linked to sites of active viral replication [19]. The damage observed in these lower-load tissues is therefore likely collateral, a consequence of the systemic inflammatory milieu rather than direct viral cytolysis. Further evidence for a systemic inflammatory state comes from the measurement of acute phase proteins (APPs). Serum amyloid A (SAA) and haptoglobin (HP) are significantly elevated in elephants with EEHV viremia, with concentrations increasing in parallel with viral load and being highest in fatal cases compared to survivors [61]. Elevated serum amyloid A is a classic biomarker of systemic inflammation and tissue damage.

The role of monocytes and macrophages in both viral dissemination and immunopathology is complex. While monocytopenia is a hallmark of the acute clinical phase, immunohistochemical analysis of tissues from EEHV-HD cases reveals a paradoxical increase in infiltration of Iba-1-positive macrophages into inflamed organs [53]. This suggests that while circulating monocytes are depleted (likely due to recruitment to tissues or viral-induced apoptosis), tissue-resident macrophages are actively participating in the inflammatory response. Furthermore, viral particles have been observed in the cytoplasm of monocytes from persistently infected elephants, and peripheral blood mononuclear cells (PBMCs) from such animals show up-regulated TNF-α and IFN-γ mRNA expression [53]. This indicates that monocytes/macrophages may serve not only as effectors of inflammation but also as vehicles for viral dissemination [11, 51, 53]. The increased cellular apoptosis observed in PBMCs of EEHV-HD cases, when compared to negative controls, further underscores the profound impact of the virus on the host's immune cell populations [53].

The Role of Stress, Oxidative Stress, and Latency Reactivation

The transition from asymptomatic, latent infection to acute, fulminant EEHV-HD is not random; it is believed to be triggered by factors that compromise the host's immune surveillance. Stress, broadly defined, has long been speculated to be a critical precipitating factor. Management-derived social changes, such as between-herd and within-herd movements, significantly increase the odds of EEHV recrudescence and shedding [8]. Within-herd movements (e.g., mixing a new bull with a cow herd for breeding) pose the most significant risk, with an odds ratio of 6.86 for reactivation [8]. This suggests that the social and psychological stress of novel introductions can disrupt the delicate balance between viral latency and host immune control.

At a molecular level, the link between stress and susceptibility may be mediated by glucocorticoids and oxidative stress. A longitudinal study of one calf that developed fatal EEHV-HD during the monitoring period revealed that concentrations of salivary cortisol and fecal glucocorticoid metabolites (fGCM) were paradoxically lower in the 12 days before viremia was detected, compared to periods of health [2]. This counterintuitive finding suggests that an inability to mount an appropriate stress response, or perhaps an exhaustion of the adrenal axis, may be a risk factor. In contrast, other studies have shown that EEHV shedding events are associated with higher concentrations of reactive oxygen species (ROS) and malondialdehyde (MDA), markers of oxidative stress [60]. A moderate negative correlation was also observed between 8-hydroxydeoxyguanosine (8-OHdG), a marker of oxidative DNA damage, and the PCR threshold cycle of EEHV shedding, indicating that oxidative damage may facilitate viral reactivation [60]. Seasonal variations in oxidative stress markers, with peaks in the summer, may explain the observed higher incidence of EEHV detection during that season in some studies [41, 60].

The fundamental question of whether fatal disease results from a primary infection or reactivation of a latent virus has been largely resolved. Using a luciferase immunoprecipitation system (LIPS) assay, multiple studies have demonstrated that elephants succumbing to EEHV-HD are seronegative for the specific EEHV species that caused their illness [31, 40]. This provides definitive evidence that these are primary infections occurring in immunologically naive animals, rather than reactivation events. The waning of maternally derived antibodies, which typically occurs between 1 and 4 years of age, creates a critical window of vulnerability [26, 40]. If a naive calf encounters a high viral load during this window, it lacks the primed adaptive immune response necessary to control the infection, allowing the virus to replicate unchecked in endothelial cells and trigger the catastrophic cascade of DIC and cytokine storm. This is further supported by the observation that adult elephants, which are universally seropositive and latently infected, can undergo recrudescence and shed virus without developing clinical disease [8, 38, 40].

Diagnostic Approaches for EEHV: Molecular Detection, Serology, and Hematological Biomarkers

The diagnostic landscape for elephant endotheliotropic herpesvirus (EEHV) has evolved dramatically over the past two decades, driven by the urgent need to detect infection before the onset of fulminant hemorrhagic disease (EEHV-HD). Given that EEHV-HD can progress from subclinical viremia to death within 24–72 hours, the diagnostic armamentarium must be rapid, sensitive, and deployable across diverse settings, from well-equipped zoo veterinary hospitals to field laboratories in range countries. No single modality suffices; rather, an integrated approach combining molecular detection of viral nucleic acids, serological profiling of antibody responses, and continuous monitoring of hematological and hemostatic biomarkers provides the most comprehensive framework for clinical decision-making, epidemiological surveillance, and research into pathogenesis.

Molecular Detection: Quantitative PCR, LAMP, and In Situ Hybridization

The cornerstone of EEHV diagnostics remains the detection of viral DNA, primarily through quantitative real-time polymerase chain reaction (qPCR) targeting highly conserved regions of the viral genome. The terminase gene and the DNA polymerase (U38) gene have emerged as the most robust targets, offering high sensitivity and specificity across multiple EEHV species and subtypes [10, 24, 38]. The National Elephant Herpesvirus Laboratory in Washington, DC, has validated standardized qPCR protocols that are used globally, enabling comparison of viral loads across institutions and studies [7, 57]. Viral load quantification is expressed as viral genome equivalents per milliliter (vge/mL) of blood, with thresholds increasingly refined to differentiate subclinical viremia from clinically significant infection. For instance, low-level viremia (below approximately 20,000 vge/mL) may be associated with transient, controlled infection, whereas high-level viremia (above that threshold) correlates strongly with progression to hemorrhagic disease [55].

The choice of sample matrix is critical. Whole blood is the standard for detecting systemic viremia, but trunk washes (respiratory secretions) are the most sensitive non-invasive sample for detecting viral shedding, particularly for EEHV1 and EEHV4 [27, 57, 58]. Oral swabs have proven markedly less sensitive than trunk washes for detecting active shedding [57]. Feces have recently emerged as a novel, entirely non-invasive matrix for detecting EEHV excretion, with the first evidence of detectable viral DNA in fecal samples from captive Asian elephants in Thailand [62]. This finding is particularly important for surveillance in free-ranging populations where blood collection is impractical. Chewed plant samples have also yielded detectable herpesvirus DNA, though primarily for elephant gammaherpesvirus-1 rather than EEHV [63]. For postmortem diagnosis, tissues such as heart, liver, and tongue consistently yield the highest viral loads, with heart tissue often showing the greatest signal intensity [24, 30, 54]. The mesenteric lymph nodes have been identified as a site of particularly high viral replication in co-infection cases [48].

Beyond conventional qPCR, loop-mediated isothermal amplification (LAMP) has advanced as a point-of-care alternative suitable for resource-limited environments. A duplex real-time LAMP assay targeting EEHV1 and EEHV5 demonstrated a limit of detection of 30 copies per reaction for EEHV1 and 189 copies for EEHV5, with 100% concordance with qPCR in clinical validation using 22 elephant samples [18]. The assay requires no thermocycler, can be completed within 30 minutes, and exhibits no cross-reactivity with nine other herpesviruses. A further refinement, Direct-LAMP, eliminates the DNA extraction step entirely by using heparinized plasma directly as the template, achieving a detection limit of approximately 101.3 copies/μL and reducing turnaround time to under an hour [67]. This innovation is transformative for field deployment, where laboratory infrastructure is absent.

For archival formalin-fixed, paraffin-embedded tissues, RNAscope in situ hybridization (ISH) has been validated as a powerful tool for detecting EEHV1A RNA at the cellular level [54]. Using probes targeting the terminase and DNA polymerase genes, ISH can localize viral RNA to endothelial cell nuclei with exquisite specificity, confirming that endothelial cells are the exclusive site of viral replication in acute hemorrhagic disease [4, 54]. The terminase probe yields greater signal intensity than the DNA polymerase probe, and heart tissue consistently shows more abundant signal than tongue [54]. ISH has been instrumental in elucidating tissue tropism, demonstrating that viral replication is most abundant in heart and liver, with intermediate levels in tongue, lymph node, spleen, and gastrointestinal tract, and minimal or absent signal in kidney, salivary gland, and brain [4].

For genomic characterization and epidemiological tracking, targeted enrichment of EEHV DNA followed by next-generation sequencing is now feasible even from samples with low viral loads. A method employing ultracentrifugation to concentrate viral particles prior to DNA extraction has proven effective for enriching EEHV DNA from clinical samples, enabling complete genome sequencing that would otherwise be confounded by host DNA contamination [14]. This approach has revealed substantial genetic diversity among EEHV strains, including novel variants of EEHV1A and EEHV5, and has identified distinct subtypes circulating in different geographic regions [22, 35, 39, 42].

Serological Approaches: ELISA, LIPS, and Species-Specific Antibody Profiling

Serology provides the critical complement to molecular detection by revealing prior exposure, latent infection, and immune status. The development of serological assays has been hampered by the inability to culture EEHV in vitro, necessitating the use of recombinant viral proteins as antigens [6, 42, 52]. Glycoprotein B (gB) has been the most extensively employed antigen due to its conservation across EEHV species and its immunogenicity in naturally infected elephants [5, 11, 38, 49]. Multiple gB-based indirect ELISAs have been developed and validated, consistently demonstrating that virtually all subadult and adult elephants in captive and semi-captive populations are seropositive, indicating universal exposure [26, 38]. However, gB-specific antibodies are highly cross-reactive among EEHV species, limiting their ability to discriminate between infections with different viral types [25].

The critical advance in serological diagnostics has been the recognition that the gH/gL glycoprotein complex elicits species-specific antibody responses. A landmark study comparing gB and gH/gL ELISAs across 396 sera from 164 Asian elephants found that while gB antibodies correlated strongly across EEHV species, gH/gL antibodies were far less cross-reactive and could reliably distinguish between infections with different EEHV subtypes [25]. This distinction has profound clinical implications: elephants that succumbed to EEHV-HD consistently exhibited low or undetectable gH/gL antibodies against the specific EEHV species that caused their fatal infection, even when gB antibody levels were high. Thus, gH/gL-based ELISAs can identify individual animals at risk for developing hemorrhagic disease upon exposure to a particular EEHV species [25].

The luciferase immunoprecipitation system (LIPS) represents a further refinement, offering quantitative, high-throughput serological profiling using recombinant viral proteins fused to luciferase. LIPS assays targeting EEHV1-specific proteins have resolved the longstanding question of whether lethal infections result from primary infection or reactivation of latent virus: elephants dying from EEHV-HD were seronegative for the infecting EEHV species, confirming that fatalities occur during primary infection, not recrudescence [40]. This assay has also been adapted for EEHV3 in African elephants, demonstrating that seronegative status for EEHV3 is a risk factor for fatal disease, while seropositive animals that become infected survive [13, 31]. The ability to monitor serostatus over time has revealed that maternal antibodies wane between 1 and 4 years of age in European zoo elephants, creating a window of vulnerability that coincides with the peak incidence of EEHV-HD [26, 40].

Nonstructural protein-based ELISAs offer an alternative strategy for detecting active or recent infection rather than historical exposure. An indirect ELISA using partial EEHV DNA polymerase nonstructural proteins demonstrated 77.9% sensitivity and 87.7% specificity compared to PCR, and identified 14% seropositivity among PCR-negative, clinically healthy elephants, suggesting that these animals had experienced recent active infection and could serve as shedders [50]. Similarly, a competitive ELISA format using truncated fragments of DNA polymerase, gB, and gL showed that hyperimmune sera raised against these antigens could consistently differentiate known positive from negative samples, with an apparent seroprevalence of 10% in a survey of 270 elephants in India [6, 16].

An immunochromatographic strip test (ICS) has been developed for rapid antigen detection in the field, using colloidal gold-conjugated anti-EEHV DNA polymerase antibodies. This test can detect EEHV antigen at a concentration of 1.25 × 10⁵ viral genome copies/mL in blood samples, requires no specialized equipment, and provides results in minutes [56]. While less sensitive than qPCR, the ICS test is invaluable in settings where laboratory access is limited, enabling rapid triage and initiation of therapy.

Hematological Biomarkers: The Hemostatic and Inflammatory Axis

The hematological profile of EEHV infection is not merely a diagnostic tool but a window into the pathophysiological processes driving hemorrhagic disease. The hallmark of EEHV-HD is a consumptive coagulopathy consistent with disseminated intravascular coagulation (DIC), driven by widespread endothelial cell infection, activation, and necrosis [9, 30, 36]. Thrombocytopenia is the most consistently observed and clinically actionable hematological abnormality. Platelet counts decline precipitously as disease progresses, often falling to levels below 50 × 10⁹/L in fatal cases, and the rate of decline is more prognostically informative than any single absolute value [10, 46, 68]. Automated platelet counts in healthy juvenile Asian elephants show a mean of approximately 385 × 10⁹/L, with reference intervals established for both Asian and African elephants, enabling objective detection of thrombocytopenia [1].

Monocytopenia has emerged as an early and sensitive indicator of impending clinical disease, often preceding detectable viremia by several days [2, 3, 43, 46]. In a landmark longitudinal study of biological variation in African elephants, the reference change value (RCV) for monocytes was calculated, and a retrospective analysis of an EEHV2 case revealed that monocytopenia was detected by RCV analysis before the complete blood count fell outside population-based reference intervals [3]. This finding underscores the high individuality of hematology parameters in elephants and the superiority of individual baseline monitoring over population-derived intervals. Lymphocytopenia similarly occurs early in infection, often accompanied by the appearance of immature band heterophils, reflecting a left shift in the heterophil lineage [13, 20, 46].

The monocyte-to-heterophil (M:H) ratio has been proposed as a practical metric for clinical decision-making. In a retrospective analysis of 103 EEHV cases in Thailand, severely affected elephants exhibited an M:H ratio below 2.37, which distinguished animals at high risk of mortality [10]. The depletion of monocytes may reflect their role as vehicles for viral dissemination; EEHV DNA polymerase antigens have been localized within monocytic lineage cells, and viral particles have been observed in the cytoplasm of monocytes from persistently infected elephants [11, 51, 53]. Apoptosis of peripheral blood mononuclear cells is markedly increased in EEHV-HD cases, contributing to the lymphocytopenia and monocytopenia [53].

The hemostatic derangement extends beyond platelet consumption. D-dimer concentrations rise dramatically in acute EEHV-HD, reflecting active fibrinolysis of cross-linked fibrin clots formed during DIC [9, 30, 65]. Reference intervals for D-dimer in healthy juvenile elephants have been established: no significant difference exists between Asian and African elephants, with values typically below 0.5 μg/mL [1]. Fibrinogen concentrations, in contrast, may be variable. Asian elephants have significantly higher baseline fibrinogen levels (mean 320 mg/dL) than African elephants (mean 256 mg/dL), and within African elephants, males have higher fibrinogen than females [1]. In acute EEHV-HD, fibrinogen may be consumed, contributing to the coagulopathy. Thromboelastography has been used to assess global hemostatic function, demonstrating hypofibrinolysis in treated cases, which may inform the use of antifibrinolytic agents such as aminocaproic acid [65].

Cardiac troponin I (cTnI) has emerged as a biomarker of myocardial injury secondary to the profound endothelial damage and microvascular thrombosis characteristic of EEHV-HD. In a study of 53 blood samples from 37 Asian elephants, cTnI was detectable only in animals with high-level viremia (≥20,000 vge/mL), and its presence correlated strongly with clinical signs of hemorrhagic disease [55]. Sequential sampling during viremic events showed rising cTnI concentrations as disease progressed, suggesting that cTnI may help differentiate subclinical viremia from impending hemorrhagic disease and guide the timing of aggressive therapeutic intervention.

Acute phase proteins, particularly serum amyloid A (SAA) and haptoglobin, are elevated in elephants with EEHV viremia and increase with viral load. In a study of 14 EEHV-infected elephants, SAA and haptoglobin concentrations were significantly higher in fatal cases compared to survivors, suggesting that these markers may have prognostic utility [61]. Cytokine profiling has revealed elevated mRNA levels of IL-6, IL-10, and IFN-γ in blood and tissues with high viral loads, consistent with a cytokine storm syndrome that contributes to the systemic inflammatory response and multi-organ dysfunction [19, 61]. The upregulation of these cytokines is spatially associated with sites of active viral replication, particularly in the heart and liver, implicating localized cytokine production in tissue damage [19].

The evolving understanding of these hematological and hemostatic biomarkers has led to the development of an overt DIC scoring system adapted from the International Society on Thrombosis and Hemostasis (ISTH) criteria. The foundational reference intervals for platelet count, D-dimer, and fibrinogen in healthy juvenile elephants provide the normative data required to assign points for thrombocytopenia, elevated fibrin degradation products, and prolonged prothrombin time or decreased fibrinogen, thereby enabling objective classification of DIC severity in EEHV-HD [1]. The retrospective application of this scoring system to fatal European cases confirmed that overt DIC is present in the majority of EEHV-HD fatalities, with microthrombi identified histologically in 63% of cases [30].

The World Organisation for Animal Health (WOAH) recognizes EEHV as a significant emerging disease of conservation concern, and the integration of molecular, serological, and hematological diagnostics aligns with WOAH standards for surveillance and disease confirmation. The hematological monitoring protocols developed for EEHV are among the most sophisticated in wildlife medicine, drawing on principles of biological variation and reference change values that are more commonly applied in human clinical pathology. The high individuality of hematology parameters in elephants, demonstrated in both Asian and African species, necessitates the establishment of individual baseline values for each at-risk calf, with serial monitoring enabling detection of subtle deviations that precede overt clinical signs [3, 34]. The RCV, which accounts for both analytical and biological variation, provides a statistically robust threshold for identifying significant changes in monocyte, lymphocyte, and platelet counts, and has been shown to detect clinically meaningful abnormalities that would be missed by population-based reference intervals [3].

In summary, the diagnostic framework for EEHV is a multilayered system that leverages the strengths of molecular detection for early identification and quantification of viremia, serological profiling for risk stratification and epidemiological surveillance, and hematological biomarkers for real-time monitoring of disease progression and hemostatic status. The integration of these modalities, guided by species-specific reference intervals, individual baselines, and an understanding of the underlying pathophysiological processes, enables clinicians to initiate treatment at the earliest possible moment, improve survival outcomes, and generate data essential for advancing vaccine development and herd management strategies.

Hematological Reference Intervals and Monitoring in Juvenile Elephants

The establishment and application of robust hematological reference intervals (RIs) are foundational to the clinical management of juvenile elephants, particularly in the context of elephant endotheliotropic herpesvirus hemorrhagic disease (EEHV-HD). The utility of these intervals extends far beyond simple diagnostic categorization; they are the linchpin of early detection, prognostication, and therapeutic decision-making for a disease that can progress from subclinical viremia to fatal hemorrhagic shock within hours. The unique pathophysiology of EEHV-HD, characterized by a targeted infection of endothelial cells leading to disseminated intravascular coagulation (DIC) and a cytokine storm, necessitates a hematological monitoring paradigm that is both species-specific and dynamically interpreted against individual baselines [4, 9, 19, 30].

Foundational Reference Intervals and the Challenge of Individuality

The cornerstone of any monitoring program is a reliable set of RIs. For juvenile elephants, these must be stratified not only by species, Elephas maximus and Loxodonta africana, but also by age, given the profound physiological changes during growth. Foundational work by Bercier et al. [1] established critical RIs for D-dimer concentration, fibrinogen concentration, and automated platelet count in healthy juvenile Asian and African elephants. This study is particularly significant because these three analytes are integral to the International Society on Thrombosis and Hemostasis (ISTH) overt DIC scoring system, a framework directly applicable to the coagulopathy seen in EEHV-HD. The study revealed species-specific differences, with Asian elephants exhibiting significantly higher fibrinogen concentrations than their African counterparts, and a moderately strong positive correlation between platelet count and age in African elephants [1]. These data provide the essential baseline for evaluating the hemostatic derangements that define severe EEHV-HD.

However, a critical nuance that has emerged from recent research is the concept of biological variation and the high individuality of hematology parameters. Browning et al. [3] demonstrated that in African elephants, most hematology parameters display intermediate-to-high individuality. This means that a single value falling within a broad population-derived RI may actually represent a significant pathological change for that individual. Conversely, a value outside the population RI might be normal for a particular animal. This finding has profound implications for EEHV monitoring. In a retrospective analysis of an EEHV-HD case, Browning et al. [3] showed that individual normal values and calculated reference change values (RCV) detected clinically significant monocytopenia, leukopenia, and thrombocytopenia associated with EEHV2 viremia, even though none of these parameters fell outside the population-derived RI. This underscores the inadequacy of relying solely on static population RIs and champions the use of serial individual baselines and RCVs as a more sensitive diagnostic tool for detecting the early hematological signatures of EEHV infection.

The Hematological Signature of EEHV Infection: A Window into Pathogenesis

The hematological changes observed during EEHV infection are not random; they are a direct reflection of the virus's tropism and the host's response. The virus's exclusive targeting of capillary endothelial cells leads to widespread vascular damage, which in turn triggers a cascade of events detectable in the peripheral blood [4, 9]. The most consistently reported and prognostically significant finding is thrombocytopenia. This is a hallmark of EEHV-HD and is a direct consequence of platelet consumption in the microthrombi that characterize the DIC-like state [9, 30]. Perrin et al. [30] found microthrombi in 63% of EEHV-HD cases in a large retrospective review, directly linking the hematological finding of low platelet counts to the pathological process of disseminated intravascular coagulation. The severity of thrombocytopenia often correlates with disease outcome; a continuous sharp decline in platelet count is a grave prognostic indicator, as noted by Dastjerdi et al. [46] in their comparison of surviving and fatal EEHV-1A cases. In some instances, a paradoxical thrombocytosis has been observed in subclinical or recovering cases, such as the long-term, intermittent, low-level viremia documented by Bauer et al. [69], where an elevated platelet count was a persistent feature. This may represent a reactive, rebound phenomenon or a component of a chronic, controlled infection.

Beyond platelets, the monocyte and lymphocyte populations are exquisitely sensitive indicators of active EEHV infection. A profound monocytopenia is one of the earliest and most reliable harbingers of impending clinical disease, often preceding detectable viremia by several days [10, 43, 46]. This finding is mechanistically linked to the virus's tropism for cells of the monocyte/macrophage lineage. Srivorakul et al. [53] demonstrated that monocytes may serve as a vehicle for viral dissemination, with viral particles observed in their cytoplasm. The depletion of circulating monocytes likely reflects their recruitment to sites of infection and their role as targets for viral replication and subsequent cell death. Similarly, lymphocytopenia is a frequent finding, reflecting both the direct cytopathic effects of the virus on infected cells and the systemic inflammatory response that leads to lymphocyte apoptosis [2, 13, 53]. The depletion of these leukocyte populations is so characteristic that a monocyte:heterophil (M:H) ratio lower than 2.37 has been identified as a marker of severe disease in Asian elephants [10].

Conversely, the heterophil (the elephant equivalent of the neutrophil) population often shows a left shift, with the emergence of immature band heterophils and evidence of heterophil toxicity [10, 13, 20, 66]. This is a non-specific sign of systemic inflammation and a bone marrow response to the acute demand for phagocytic cells. The presence of toxic heterophils, characterized by cytoplasmic basophilia and vacuolation, is a common finding in severe, acute EEHV-HD cases and reflects the severity of the systemic inflammatory state [10, 66]. The overall leukopenia that results from the combined lymphopenia, monocytopenia, and heterophil depletion is a powerful signal that the host's immune system is being overwhelmed, as seen in fatal cases across multiple EEHV subtypes [13, 20, 21].

Advanced Hemostatic and Inflammatory Biomarkers

The hematological picture of EEHV-HD is not complete without an assessment of the coagulation and fibrinolytic systems. The DIC-like state is characterized by consumption of clotting factors and activation of fibrinolysis. D-dimer, a fibrin degradation product, is a sensitive marker of this process. Bercier et al. [1] established RIs for D-dimer in healthy elephants, providing a baseline against which to measure the marked elevations expected during EEHV-HD. Similarly, fibrinogen, an acute phase protein, can be consumed in the clotting process, leading to hypofibrinogenemia in severe DIC, although its levels can also be elevated as part of the acute phase response. The work by Iyer et al. [65] in a successfully treated case of EEHV1A-HD demonstrated the utility of thromboelastography (TEG) to assess global hemostatic function, revealing hypofibrinolysis and guiding the use of the antifibrinolytic agent aminocaproic acid. This advanced monitoring technique, while not widely available, offers a real-time assessment of clot strength and stability that can directly inform therapeutic interventions.

Furthermore, the systemic inflammation that accompanies endothelial damage is reflected in elevated levels of acute phase proteins (APPs) . Edwards et al. [61] showed that serum amyloid A (SAA) and haptoglobin (HP) were significantly higher in elephants with EEHV viremia compared to those without, with concentrations increasing with viral load and being highest in fatal cases. These APPs can serve as non-specific but sensitive indicators of disease severity and progression. Cardiac troponin I (cTnI) has also emerged as a critical biomarker, directly reflecting the myocardial damage that is a common cause of death in EEHV-HD. Anderson et al. [55] found a significant association between high-level EEHV1 viremia and detectable cTnI, with values correlating with the presence of clinical signs. This biomarker provides a direct link between the hematological monitoring and the pathological endpoint of cardiac failure.

Practical Implementation of a Monitoring Protocol

Given the rapid progression of EEHV-HD, a monitoring protocol must be proactive, systematic, and individualized. The evidence strongly supports a shift from reactive testing to routine, longitudinal surveillance. For at-risk juvenile elephants (typically 1–10 years of age), a baseline complete blood count (CBC) with a manual differential and platelet estimate should be established when the animal is healthy. This individual baseline is more valuable than any population RI. Serial monitoring, often weekly or even daily during periods of known risk (e.g., weaning, social changes, seasonal peaks), should focus on the dynamic trends in monocyte, lymphocyte, and platelet counts. A significant drop in any of these parameters, even if still within the population RI, should trigger immediate qPCR testing for EEHV [3, 43]. The use of in-house blood smear analysis, as advocated by Wissink-Argilaga et al. [43], allows for immediate assessment of platelet numbers, white blood cell morphology, and the presence of toxic heterophils, enabling rapid decision-making without waiting for automated analyzer results.

The integration of these hematological parameters with viral load data (qPCR) and serological status (e.g., gH/gL-specific antibody levels) creates a powerful multi-dimensional monitoring framework. Low antibody levels against the infecting EEHV subtype are a major risk factor for developing fatal disease, as they indicate a primary infection in a naïve host [25, 26, 40]. Therefore, a juvenile elephant with low EEHV-specific antibodies, a declining monocyte count, and a detectable but low-level viremia is at far higher risk than one with high antibody titers and stable hematology. This integrated approach, which moves beyond simple reference intervals to embrace biological variation, individual baselines, and a panel of specific biomarkers, represents the current state-of-the-art in EEHV monitoring and is essential for improving survival outcomes in this devastating disease.

Current Therapeutic Strategies and Preventive Measures for EEHV

The management of elephant endotheliotropic herpesvirus hemorrhagic disease (EEHV-HD) represents one of the most formidable challenges in contemporary wildlife medicine, demanding a multifaceted approach that integrates rapid diagnostic capabilities, aggressive antiviral chemotherapy, sophisticated supportive care, and increasingly, proactive immunological interventions. The therapeutic landscape has evolved considerably over the past two decades, driven by the recognition that survival hinges upon early detection and the immediate institution of combined treatment modalities. Nevertheless, the fundamental limitations imposed by the inability to cultivate EEHV in vitro [42, 52] and the paucity of pharmacokinetic data in elephants continue to constrain therapeutic optimization. Current strategies are best conceptualized as operating along a continuum: from acute intervention during fulminant viremia to long-term preventive measures aimed at modulating host susceptibility and reducing viral transmission within managed populations.

Antiviral Chemotherapy: Nucleoside Analogues and Beyond

The cornerstone of specific antiviral therapy against EEHV remains the nucleoside analogue family, particularly acyclovir, its prodrug valacyclovir, famciclovir (the prodrug of penciclovir), and ganciclovir. These drugs, originally developed for human herpesviruses, function as chain terminators following triphosphorylation by viral thymidine kinase, thereby inhibiting viral DNA polymerase. The extrapolation of dosing regimens from human and domestic animal medicine has been pragmatic but fraught with uncertainty, given the absence of controlled efficacy trials in elephants.

Famciclovir has been the most extensively utilized agent in clinical practice, often administered at empirical doses of 15 mg/kg rectally, twice daily [46]. However, its efficacy has been called into serious question. Dastjerdi et al. (2016) documented two cases of EEHV-1A infection in juvenile Asian elephants treated with rectal famciclovir, wherein detectable penciclovir levels were achieved in the blood, yet one calf succumbed to fulminant disease [46]. The authors concluded that rectal famciclovir appeared insufficient to halt disease progression in clinical cases, particularly once marked hematological derangements were established, and advocated for alternative antivirals or complementary strategies such as plasma infusions if no improvement in viral load or blood parameters was observed within the initial days of viremia [46]. This underscores a critical clinical reality: the window for effective antiviral intervention is extraordinarily narrow, and prodrugs requiring gastrointestinal absorption and hepatic conversion may be unreliable in calves already exhibiting systemic compromise and potential gastrointestinal edema.

In contrast, acyclovir has demonstrated notable success in specific contexts. Khammesri et al. (2020) reported the successful treatment of a 2-year, 11-month-old female Asian elephant presenting with facial edema, mild fever, and high EEHV-1A viral load using oral acyclovir at a dose of 45 mg/kg three times daily for 28 days [66]. The viral load declined to undetectable levels within nine days, and the calf survived, marking the first documented successful outcome with oral acyclovir [66]. The authors highlighted the practical advantages of oral administration, particularly in untrained calves where repeated intravenous catheterization is challenging. Ganciclovir, administered intravenously twice daily, has also been employed with apparent benefit. Wissink-Argilaga et al. (2019) described a case of EEHV-1B infection where twice-daily intravenous ganciclovir, combined with plasma transfusions and fluid therapy, coincided with a decreasing viral load and clinical recovery [43]. The temporal association between drug administration and viral clearance, while not proof of causality, provides pragmatic support for its continued use in critical settings.

A fundamental limitation pervading all current antiviral strategies is the lack of in vitro sensitivity data. Since EEHV cannot be reliably propagated in continuous cell lines beyond limited early passages in U937 cells [52], conventional plaque reduction assays to determine IC50 values for these drugs against EEHV are not feasible. Clinicians must therefore rely on extrapolation from related betaherpesviruses (e.g., human cytomegalovirus), which are generally less sensitive to acyclovir than alphaherpesviruses, and on anecdotal clinical reports. The development of a cell culture system for EEHV isolation and drug sensitivity testing remains a critical unmet need for advancing rational therapeutic design [42, 52].

Managing the Hemostatic Catastrophe: Disseminated Intravascular Coagulation and Plasma Therapy

EEHV-HD is fundamentally a disease of the microvasculature. The exclusive tropism of EEHV for capillary endothelial cells, confirmed through RNAscope in situ hybridization demonstrating viral nucleic acid within endothelial nuclei of the heart, liver, tongue, and other organs [4, 54], initiates a cascade of vascular injury, exposure of subendothelial collagen, platelet activation, and consumption. The resultant disseminated intravascular coagulation (DIC) is now recognized as a central pathophysiological driver of mortality. Perrin et al. (2021) provided the most substantive evidence to date, demonstrating microthrombi in 63% of 27 European EEHV-HD fatalities across multiple organs, including the lungs, and correlating these findings with widespread hemorrhage and the thrombocytopenia consistently documented in clinical cases [30]. Guntawang et al. (2021) further elucidated the molecular mechanisms, demonstrating increased immunolabeling of platelet endothelial cell adhesion molecule-1 (PECAM-1) and von Willebrand factor (vWF) in injured vessels, alongside significant upregulation of pro-inflammatory cytokine mRNA, supporting a model of systemic inflammation driving vascular disruption and consumptive coagulopathy [9].

The therapeutic implication is profound: antiviral drugs alone are insufficient. Supportive interventions targeting the hemostatic derangement are arguably equally critical. Fresh-frozen plasma (FFP) transfusion has emerged as a mainstay of supportive care, providing replacement of consumed clotting factors, fibrinogen, and natural anticoagulants. Thitaram et al. (2026) systematically evaluated the biochemical stability of Asian elephant FFP stored at −20°C, demonstrating that fibrinogen concentrations remained stable for up to 12 months, and although factor VIII activity declined by 16% after 12 months, values remained within clinically acceptable ranges [72]. Importantly, IgG and albumin concentrations increased during storage due to cryoconcentration, suggesting that stored plasma retains immunological and oncotic benefits [72]. These findings provide crucial evidence supporting the establishment of regional plasma banks, enabling immediate access to compatible blood products during emergencies without the logistical delays of donor recruitment and processing.

Beyond plasma, specific anti-fibrinolytic and pro-hemostatic agents are gaining consideration. Iyer et al. (2022) reported the successful use of aminocaproic acid, an inhibitor of plasminogen activation, in a severe EEHV-1A case, with thromboelastography demonstrating hypofibrinolysis following drug administration compared to healthy controls [65]. This suggests that hyperfibrinolysis may contribute to the hemorrhagic diathesis and that its inhibition could be beneficial. Additionally, the use of mesenchymal stem cells harvested from elephant umbilical tissue was explored in the same case as a novel approach to support endothelial repair, though this remains highly experimental [65]. The development and validation of an overt DIC scoring system for juvenile elephants, as recently advanced by Bercier et al. (2025) with the establishment of reference intervals for D-dimer, fibrinogen, and platelet counts [1], will be instrumental in objectively guiding the intensity of hemostatic support and monitoring treatment response.

Anti-Inflammatory and Immunomodulatory Strategies

The recognition that EEHV-HD pathophysiology involves a profound dysregulated host inflammatory response has opened new therapeutic avenues. Hoornweg et al. (2025) provided compelling evidence of significantly elevated mRNA levels of IFN-γ, IL-6, and IL-10 in blood and tissues with high viral loads (heart, liver) from fatal EEHV-HD cases, proposing that a pathogen-induced cytokine storm underlies the transition from controlled viremia to fatal systemic disease [19]. This is consistent with earlier findings of severe acute systemic inflammation in the absence of bacterial infection, observed in 27 European fatalities [30]. These data support the investigation of anti-inflammatory therapies to temper the immunological firestorm.

Corticosteroids have been employed empirically, albeit with caution due to their potential to impair antiviral immunity. Wissink-Argilaga et al. (2019) administered short-acting glucocorticosteroids for two consecutive days in a clinical EEHV-1B case and observed a subsequent reduction in lymphocytes, recovery and maturation of monocytes, and gradually decreasing clinical signs [43]. The authors suggested that glucocorticosteroids may have value in mitigating the inflammatory component of disease without completely abrogating the antiviral response, though they emphasized that decision-making was guided primarily by hematological changes rather than viral load alone [43]. The potential for non-steroidal anti-inflammatory drugs (NSAIDs) or more targeted cytokine inhibitors (e.g., tocilizumab for IL-6 blockade) remains unexplored in elephants but represents a logical extension of the cytokine storm hypothesis.

An alternative immunomodulatory approach focuses on potentiating the innate antiviral response. Recognizing that the rapid progression of EEHV-HD often precludes an effective adaptive immune response, Haycock et al. (2025) sequenced and recombinantly expressed Asian elephant interferon alpha (IFNα) and interferon beta (IFNβ), demonstrating that these cytokines could protect primary Asian elephant fibroblasts from bovine alphaherpesvirus-1 infection in a dose-dependent manner in vitro, even when applied up to 24 hours post-infection [44]. This proof-of-concept study suggests that recombinant elephant IFNs could be deployed as an emergency immunotherapeutic, inducing an antiviral state in endothelial cells and potentially bridging the gap until an adaptive T-cell response develops. Furthermore, Haycock et al. (2024) demonstrated that two commercially available veterinary immunostimulants, parapoxvirus ovis and CpG motif-containing bacterial plasmid DNA, could upregulate innate immune gene expression (including CXCL10, ISG15, and Mx1) in Asian elephant blood cells [68]. These agents, already licensed for use in domestic species for their immunomodulatory properties, could theoretically be administered prophylactically to at-risk calves during periods of heightened stress or known exposure to reduce the risk of fulminant disease.

Supportive Care and Critical Monitoring

Beyond specific pharmacotherapies, meticulous supportive care is indispensable. Fluid therapy to maintain perfusion, nutritional support, and management of secondary infections are standard. The monitoring of cardiac troponin I (cTnI) has emerged as a valuable tool for assessing myocardial damage. Anderson et al. (2022) demonstrated that detectable cTnI was significantly associated with high-grade viremia (≥20,000 vge/mL) and the presence of clinical signs, with rising troponin values correlating with disease progression [55]. This biomarker can help differentiate subclinical viremia from incipient EEHV-HD, guiding the decision to escalate therapy. Similarly, the acute phase proteins serum amyloid A (SAA) and haptoglobin (HP) were shown to increase with viral load and were higher in fatal cases compared to survivors, offering additional prognostic utility [61].

The importance of biological variation in interpreting hematological data cannot be overstated. Browning et al. (2024) demonstrated that most hematology parameters in African elephants exhibit intermediate-to-high individuality, meaning population-derived reference intervals are an insensitive diagnostic tool [3]. In a retrospective evaluation of an EEHV-2 case, individual normal values and calculated reference change values (RCV) detected clinically significant monocytopenia, leukopenia, and thrombocytopenia that were not identified by population reference intervals [3]. This underscores the necessity of establishing individual baseline hematological profiles for every elephant in managed care, enabling the detection of subtle yet critical pre-clinical changes that herald imminent disease.

Preventive Measures: Risk Stratification, Surveillance, and Vaccination

The most impactful strategy for reducing EEHV-HD mortality is prevention, which has coalesced around three pillars: serological risk stratification, active surveillance, and vaccination.

Serological Risk Stratification: A paradigm shift in understanding EEHV-HD has emerged from the recognition that fatal disease represents a primary infection occurring in a calf with waning or absent maternal antibodies against the specific EEHV species to which it is exposed. Fuery et al. (2019) demonstrated, using luciferase immunoprecipitation system (LIPS) assays, that elephants dying from EEHV-1 hemorrhagic disease were seronegative for the infecting species, while surviving elephants were seropositive prior to challenge [40]. This seminal finding refuted the hypothesis that fatal disease arises from reactivation of latent virus in a previously infected animal; instead, it is a consequence of immunological naivety. This has been replicated in multiple contexts. Pursell et al. (2021) showed that African elephants succumbing to EEHV-3 were seronegative for EEHV-3 prior to infection, whereas survivors were seropositive, indicating that the same paradigm applies across species and viral genotypes [31]. Similarly, Willis et al. (2025) reported that three African elephants that died from EEHV-2 were seronegative for EEHV-2, while two that survived were seropositive [13].

This serological framework enables proactive management. Calves can be monitored longitudinally for antibody levels against the major EEHV species (EEHV-1, -4, -5 for Asian elephants; EEHV-2, -3, -6, -7 for African elephants) using species-specific gH/gL ELISAs. Hoornweg et al. (2023) demonstrated that while gB-specific antibodies are highly cross-reactive, gH/gL-specific antibodies are species-specific and can identify animals at risk of succumbing to a particular EEHV species [25]. Seronegative calves, or those with declining titers, can be prioritized for intensive surveillance, minimized stress exposure, and potentially prophylactic immunostimulation. The observation that young elephants in large Sri Lankan herds maintained high antibody levels and did not succumb to EEHV-HD, while European zoo juveniles in smaller herds exhibited waning maternal antibodies and increased fatality [26], strongly suggests that natural boosting through controlled exposure to shedding adults may be protective, albeit with inherent risks.

Active Surveillance and Monitoring: Early detection of viremia before the onset of clinical signs is the single most critical factor in determining survival. Routine qPCR monitoring of blood and trunk wash samples, ideally twice weekly during high-risk periods (e.g., after weaning, transport, social introductions, and during rainy seasons [8, 41]), enables detection of rising viral loads at a stage when intervention is most likely to be effective. The development of rapid, field-deployable diagnostic tools has expanded surveillance capacity. Loop-mediated isothermal amplification (LAMP) assays, including a duplex real-time LAMP for simultaneous detection of EEHV-1 and EEHV-5 [18] and a Direct-LAMP method using heparinized plasma without DNA extraction that achieves detection in under 30 minutes [67], are invaluable in resource-limited settings. Immunochromatographic strip tests for EEHV antigen detection have also been developed, with a detection limit of 1.25 × 10⁵ viral genome copies/mL, offering a low-tech option for field screening [56]. The detection of EEHV shedding in feces [62, 63] and non-invasive chewed plant samples [63] opens possibilities for surveillance in free-ranging populations where handling is not feasible.

Husbandry and Stress Management: Stress is a well-documented trigger for herpesvirus reactivation in many species, and mounting evidence implicates it in EEHV shedding and potentially in the transition from latency to active viremia. Titus et al. (2022) demonstrated that all management-derived social changes in captive herds promoted EEHV-1 shedding, with within-herd movements (mixing a new bull with cows) posing the most significant increase in reactivation odds (OR = 6.86) [8]. This finding has direct practical implications: introductions of new animals or regrouping should be managed with extreme caution, ideally during periods when the herd is not at peak risk, and should be accompanied by intensified monitoring. Oxidative stress has also been linked to EEHV shedding; Kosaruk et al. (2023) found that shedding events were associated with higher concentrations of reactive oxygen species and malondialdehyde, and that DNA damage (8-hydroxydeoxyguanosine) correlated with viral shedding intensity [60]. This suggests that nutritional interventions to support antioxidant defenses (e.g., vitamin E, selenium) could be a low-risk, potentially beneficial adjunct. The knowledge, attitude, and practice (KAP) survey among mahouts in Thailand revealed that many handlers were confident their elephants would not get EEHV, leading to inadequate prevention measures [70]. Comprehensive education programs targeting early recognition of clinical signs, appropriate weaning age (as younger weaning may disrupt maternal antibody transfer), and transmission prevention are essential for frontline care.

Vaccine Development: The ultimate preventive measure is an effective vaccine, and the field has witnessed remarkable progress in recent years. Multiple platforms are under investigation.

The mRNA vaccine platform has shown particular promise. Watts et al. (2024) generated a multi-antigenic EEHV mRNA vaccine encoding the EEHV-1A glycoproteins gB, gH, gL, and gO, encapsulated in lipid nanoparticles. Vaccination of outbred CD-1 mice induced robust antibody titers against gB, gH, and gL, and activated both CD4+ and CD8+ T cells secreting cytokines associated with a Th1 response, without any observed adverse effects [5]. This is particularly significant because glycoproteins gH, gL, and gO constitute the core entry machinery for betaherpesviruses, and targeting multiple antigens reduces the risk of immune escape.

Subunit vaccines based on glycoprotein B (gB) have also demonstrated immunogenicity. Sittisak et al. (2025) immunized mice with EEHV-1A gB fragments (gBF1 and gBF2) corresponding to ectodomains I and IV, adjuvanted with Montanide ISA 206 VG or incomplete Freund's adjuvant. Both formulations induced strong humoral responses and predominantly activated CD4+ T cells with both Th1 (IFN-γ+) and Th2 (IL-4+) profiles, though no significant CD8+ T cell activation was observed [49]. The ability of sera from immunized mice to detect EEHV-gB ex vivo suggests that these antibodies could neutralize the virus in vivo. Importantly, Sittisak et al. (2023) had previously shown that EEHV-1A gB epitopes could stimulate proliferation of CD3+ cells and upregulation of IL-1β, IL-8, IL-12, and IFN-γ in elephant PBMCs in vitro, confirming that these antigens are recognized by the elephant immune system [71].

The most advanced vaccine candidate in terms of clinical evaluation is a heterologous, recombinant modified vaccinia virus Ankara (MVA) prime and adjuvanted protein boost vaccine developed by Maehr et al. (2025). In the world's first trial of an EEHV vaccine in elephants, this vaccine, containing the regulatory protein EE

References

[1] Bercier M, Brooks MB, Latimer EM. REFERENCE INTERVALS FOR D-DIMER CONCENTRATION, FIBRINOGEN CONCENTRATION, AND AUTOMATED PLATELET COUNT IN JUVENILE ASIAN (ELEPHAS MAXIMUS) AND AFRICAN (LOXODONTA AFRICANA) ELEPHANTS WITHOUT ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS. Journal of zoo and wildlife medicine. 2025. DOI: https://doi.org/10.1638/2024-0097

[2] Boonprasert K, Yun Y, Kosaruk W, Towiboon P, Tankaew P, Punyapornwithaya V, et al.. A Longitudinal Study of Hematology and Stress Biomarker Profiles in Young Asian Elephants (Elephas Maximus) in Relation to Elephant Endotheliotropic Herpesvirus (EEHV) in Thailand. Animals. 2021. DOI: https://doi.org/10.3390/ani11092530

[3] Browning GR, Kjelgaard-Hansen M, Howard LL, Keener L, LaFarga M, Perrin KL. BIOLOGICAL VARIATION OF HEMATOLOGY PARAMETERS AND CLINICAL APPLICATION IN AFRICAN ELEPHANTS (LOXODONTA AFRICANA). Journal of zoo and wildlife medicine. 2024. DOI: https://doi.org/10.1638/2023-0055

[4] Landolfi JA, Howard LL, Ling PD. Tissue and cellular tropism of elephant endotheliotropic herpesvirus (EEHV)1A in hemorrhagic disease. PLoS ONE. 2025. DOI: https://doi.org/10.1371/journal.pone.0330631

[5] Watts JR, Clinton JL, Pollet J, Peng R, Tan J, Ling P. Multi-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice. Vaccines. 2024. DOI: https://doi.org/10.3390/vaccines12121429

[6] Sharma K, Mathesh K, Janmeda P, Nautiyal S, Lakshmi P, Subash A, et al.. Production and characterization of biologicals for disease diagnosis and pathological evaluation of elephant endotheliotropic herpesvirus (EEHV).. Journal of Virological Methods. 2024. DOI: https://doi.org/10.1016/j.jviromet.2024.114970

[7] Kerr TJ, Heerden Jv, Goosen W, Kleynhans L, Buss P, Latimer EM, et al.. DETECTION OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS (EEHV) IN FREE-RANGING AFRICAN ELEPHANTS (LOXODONTA AFRICANA) IN THE KRUGER NATIONAL PARK, SOUTH AFRICA. Journal of Wildlife Diseases. 2023. DOI: https://doi.org/10.7589/JWD-D-22-00015

[8] Titus SE, Patterson S, Prince-Wright J, Dastjerdi A, Molenaar F. Effects of between and within Herd Moves on Elephant Endotheliotropic Herpesvirus (EEHV) Recrudescence and Shedding in Captive Asian Elephants (Elephas maximus). Viruses. 2022. DOI: https://doi.org/10.3390/v14020229

[9] Guntawang T, Sittisak T, Kochagul V, Srivorakul S, Photichai K, Boonsri K, et al.. Pathogenesis of hemorrhagic disease caused by elephant endotheliotropic herpesvirus (EEHV) in Asian elephants (Elephas maximus). Scientific Reports. 2021. DOI: https://doi.org/10.1038/s41598-021-92393-8

[10] Yun Y, Sriphiboon S, Pringproa K, Chuammitri P, Punyapornwithaya V, Boonprasert K, et al.. Clinical characteristics of elephant endotheliotropic herpesvirus (EEHV) cases in Asian elephants (Elephas maximus) in Thailand during 2006–2019. Veterinary Quarterly. 2021. DOI: https://doi.org/10.1080/01652176.2021.1980633

[11] Kochagul V, Srivorakul S, Boonsri K, Somgird C, Sthitmatee N, Thitaram C, et al.. Production of antibody against elephant endotheliotropic herpesvirus (EEHV) unveils tissue tropisms and routes of viral transmission in EEHV-infected Asian elephants. Scientific Reports. 2018. DOI: https://doi.org/10.1038/s41598-018-22968-5

[12] Rini I. CONSERVED REGION OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS (EEHV) BASED ON BIOINFORMATICS ANALYSIS. Partner. 2019. DOI: https://doi.org/10.35726/jp.v24i1.336

[13] Willis TJ, Burgdorf-moisuk A, Connolly M, Raines J, Ratliff C, Gyimesi ZS, et al.. Elephant endotheliotropic herpesvirus 2 infection in 5 African elephants (Loxodonta africana) at multiple North American zoological institutions.. American Journal of Veterinary Research. 2025. DOI: https://doi.org/10.2460/ajvr.25.02.0060

[14] Sharma K, Balaji KS, Sharma G, Pawde A, Mahajan S, Agrawal R, et al.. Targeted enrichment of Elephant Endotheliotropic Herpesvirus for complete genome sequencing in elephants.. Journal of Virological Methods. 2025. DOI: https://doi.org/10.1016/j.jviromet.2025.115230

[15] Karikalan M. Elephant endotheliotropic herpesvirus haemorrhagic disease of Asian elephants: An updated mini review. Indian Journal of Veterinary Pathology. 2025. DOI: https://doi.org/10.56093/b1zft677

[16] Sharma K, Balaji K, Mathesh K, Janmeda P, Sharma G. In-Silico prediction and characterization of Elephant endotheliotropic herpesvirus proteins for development of immunodiagnostics. Environment conservation journal. 2025. DOI: https://doi.org/10.36953/ecj.33384029

[17] Knüppel S, Balfanz F, Riedel CM, Strauss V, Hoornweg T, Dimmel K, et al.. Severe Elephant Endotheliotropic Herpesvirus 6 Associated Disease in Two African Elephants Under Human Care in Austria. Animals. 2025. DOI: https://doi.org/10.3390/ani15101482

[18] Xu C, Wang Z, Zhao Y. A duplex real-time loop-mediated isothermal amplification assay for simultaneous detection of elephant endotheliotropic herpesvirus types 1 and 5. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1651182

[19] Hoornweg T, Schaftenaar W, Ijzer J, Mulder MMP, Lugtenburg M, Beest Av, et al.. Elevated IL-6, IL-10, and IFN-γ levels in fatal elephant endotheliotropic herpesvirus – hemorrhagic disease cases suggest an excessive proinflammatory cytokine response contributes to pathogenesis. Frontiers in Immunology. 2025. DOI: https://doi.org/10.3389/fimmu.2025.1645752

[20] Fayette M, Minich DJ, Sylvester H, Latimer EM. FIRST DETECTION OF CLINICAL DISEASE DUE TO ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 7A IN TWO AFRICAN ELEPHANTS (LOXODONTA AFRICANA) IN HUMAN CARE. Journal of zoo and wildlife medicine. 2024. DOI: https://doi.org/10.1638/2023-0034

[21] Boonprasert K, Srivorakul S, Monchaivanakit N, Langkaphin W, Sripiboon S, Janyamethakul T, et al.. Characterizations of Elephant Endotheliotropic Herpesvirus Type 1A and 4 Co-Infections in Asian Elephant (Elephas maximus) Calves. Veterinary Sciences. 2024. DOI: https://doi.org/10.3390/vetsci11040147

[22] Abdelgawad A, Nascimento M, Prahl A, Flügger M, Szentiks C, Holtze S, et al.. Fatal infection caused by a genetically distinct elephant endotheliotropic herpesvirus type 5 in a captive Asian elephant in Germany. Virology Journal. 2024. DOI: https://doi.org/10.1186/s12985-024-02477-w

[23] Alkausar T, Kamelia M, Yosilia R, Anisya S, Satitiningrum Y. Elephant Endotheliotropic Herpesvirus Infection in Asian Elephants (Elephas maximus): A Review. Biosfer : Jurnal Biologi dan Pendidikan Biologi. 2024. DOI: https://doi.org/10.23969/biosfer.v9i1.15403

[24] Lakshmi PS, Karikalan M, Sharma G, Sharma K, Mohan SC, Kumar KR, et al.. Pathological and molecular studies on elephant endotheliotropic herpesvirus haemorrhagic disease among captive and free-range Asian elephants in India.. Microbial Pathogenesis. 2023. DOI: https://doi.org/10.1016/j.micpath.2023.105972

[25] Hoornweg T, Schaftenaar W, Rutten V, Haan CDd. Low gH/gL (Sub)Species-Specific Antibody Levels Indicate Elephants at Risk of Fatal Elephant Endotheliotropic Herpesvirus Hemorrhagic Disease. bioRxiv. 2023. DOI: https://doi.org/10.3390/v16020268

[26] Hoornweg T, Perera VP, Karunarathne RNS, Schaftenaar W, Mahakapuge T, Kalupahana A, et al.. Young elephants in a large herd maintain high levels of elephant endotheliotropic herpesvirus‐specific antibodies and do not succumb to fatal haemorrhagic disease. Transboundary and Emerging Diseases. 2022. DOI: https://doi.org/10.1111/tbed.14644

[27] Yang N, Bao M, Zhu B, Shen Q, Guo X, Li W, et al.. Elephant Endotheliotropic Herpesvirus 1, 4 and 5 in China: Occurrence in Multiple Sample Types and Implications for Wild and Captive Population Surveillance. Viruses. 2022. DOI: https://doi.org/10.3390/v14020411

[28] Costa T, Rocchigiani G, Zendri F, Drake GJ, Lopez J, Chantrey J, et al.. Elephant Endotheliotropic Herpesvirus 4 and Clostridium perfringens Type C Fatal Co-Infection in an Adult Asian Elephant (Elephas maximus). Animals. 2022. DOI: https://doi.org/10.3390/ani12030349

[29] Fayette M, Brenner EE, Garner M, Bowman MR, Latimer EM, Proudfoot J. ACUTE HEMORRHAGIC DISEASE DUE TO ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 3A INFECTION IN FIVE AFRICAN ELEPHANTS (LOXODONTA AFRICANA) AT ONE NORTH AMERICAN ZOOLOGICAL INSTITUTION. Journal of zoo and wildlife medicine. 2021. DOI: https://doi.org/10.1638/2020-0126

[30] Perrin K, Kristensen A, Bertelsen M, Denk D. Retrospective review of 27 European cases of fatal elephant endotheliotropic herpesvirus-haemorrhagic disease reveals evidence of disseminated intravascular coagulation. Scientific Reports. 2021. DOI: https://doi.org/10.1038/s41598-021-93478-0

[31] Pursell T, Clinton JLS, Tan J, Peng R, Qin X, Doddapaneni H, et al.. Primary Infection May Be an Underlying Factor Contributing to Lethal Hemorrhagic Disease Caused by Elephant Endotheliotropic Herpesvirus 3 in African Elephants (Loxodonta africana). Microbiology spectrum. 2021. DOI: https://doi.org/10.1128/Spectrum.00983-21

[32] Prompiram P, Wiriyarat W, Bhusri B, Paungpin W, Jairak W, Sripiboon S, et al.. The occurrence of elephant endotheliotropic herpesvirus infection in wild and captive Asian elephants in Thailand: Investigation based on viral DNA and host antibody. Veterinary World. 2021. DOI: https://doi.org/10.14202/vetworld.2021.545-550

[33] Lee M, Nathan S, Benedict L, Nagalingam P, Latimer EM, Hughes T, et al.. The first reported cases of elephant endotheliotropic herpesvirus infectious haemorrhagic disease in Malaysia: case report. Virology Journal. 2021. DOI: https://doi.org/10.1186/s12985-021-01694-x

[34] Jesus SA, Doherr M, Hildebrandt T. Elephant Endotheliotropic Herpesvirus Impact in the European Asian Elephant (Elephas maximus) Population: Are Hereditability and Zoo-Associated Factors Linked with Mortality?. Animals. 2021. DOI: https://doi.org/10.3390/ani11102816

[35] Stremme C, Priadi A, Hayward G, Zachariah A. IDENTIFICATION OF TWO LETHAL CASES OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS HEMORRHAGIC DISEASE IN SUMATRAN ELEPHANT CALVES IN INDONESIA. Journal of zoo and wildlife medicine. 2021. DOI: https://doi.org/10.1638/2020-0003

[36] Sahoo N, Sahu SK, Das AK, Mohapatra D, Panda S, Gupta S, et al.. ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS HEMORRHAGIC DISEASE OUTBREAK IN AN INDIAN ZOO. Journal of zoo and wildlife medicine. 2021. DOI: https://doi.org/10.1638/2020-0156

[37] Atkins L, Zong J, Tan J, Mejia A, Heaggans SY, Nofs S, et al.. ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 5, A NEWLY RECOGNIZED ELEPHANT HERPESVIRUS ASSOCIATED WITH CLINICAL AND SUBCLINICAL INFECTIONS IN CAPTIVE ASIAN ELEPHANTS (ELEPHAS MAXIMUS). Journal of zoo and wildlife medicine. 2013. DOI: https://doi.org/10.1638/1042-7260-44.1.136

[38] Hoornweg T, Schaftenaar W, Maurer G, Doel PBvd, Molenaar F, Chamouard-Galante A, et al.. Elephant Endotheliotropic Herpesvirus Is Omnipresent in Elephants in European Zoos and an Asian Elephant Range Country. bioRxiv. 2020. DOI: https://doi.org/10.3390/v13020283

[39] Oo Z, Aung YH, Aung TT, San N, Tun Z, Hayward G, et al.. Elephant Endotheliotropic Herpesvirus Hemorrhagic Disease in Asian Elephant Calves in Logging Camps, Myanmar. Emerging Infectious Diseases. 2020. DOI: https://doi.org/10.3201/eid2601.190159

[40] Fuery A, Pursell T, Tan J, Peng R, Burbelo P, Hayward G, et al.. Lethal Hemorrhagic Disease and Clinical Illness Associated with Elephant Endotheliotropic Herpesvirus 1 Are Caused by Primary Infection: Implications for the Detection of Diagnostic Proteins. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.01528-19

[41] Hengtrakul P, Sudlapa P, Chaisurat N, Sodsaengthien S, Chamnankij C, Noimoon S, et al.. Biological and environmental factors associated with the detection of elephant endotheliotropic herpesvirus in Asian elephants (Elephas maximus) in Thailand. Journal of Veterinary Medical Science. 2020. DOI: https://doi.org/10.1292/jvms.20-0309

[42] Pavulraj S, Eschke K, Prahl A, Flügger M, Trimpert J, Doel PBvd, et al.. Fatal Elephant Endotheliotropic Herpesvirus Infection of Two Young Asian Elephants. Microorganisms. 2019. DOI: https://doi.org/10.3390/microorganisms7100396

[43] Wissink-Argilaga N, Dastjerdi A, Molenaar F. USING IN-HOUSE HEMATOLOGY TO DIRECT DECISION-MAKING IN THE SUCCESSFUL TREATMENT AND MONITORING OF A CLINICAL AND SUBSEQUENTLY SUBCLINICAL CASE OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 1B.. Journal of zoo and wildlife medicine. 2019. DOI: https://doi.org/10.1638/2018-0096

[44] Haycock J, Maehr T, Dastjerdi A, Steinbach F. Asian elephant interferons alpha and beta and their anti-herpes viral activity. Frontiers in Immunology. 2025. DOI: https://doi.org/10.3389/fimmu.2025.1533038

[45] Fuery A, Leen A, Peng R, Wong M, Liu H, Ling P. Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus. Journal of Virology. 2017. DOI: https://doi.org/10.1128/JVI.01951-17

[46] Dastjerdi A, Seilern-Moy K, Darpel K, Steinbach F, Molenaar F. Surviving and fatal Elephant Endotheliotropic Herpesvirus-1A infections in juvenile Asian elephants – lessons learned and recommendations on anti-herpesviral therapy. BMC Veterinary Research. 2016. DOI: https://doi.org/10.1186/s12917-016-0806-5

[47] Bhusri B, Suksai P, Mongkolphan C, Tiyanun E, Ratanakorn P, Chaichoun K, et al.. Detection of elephant endotheliotropic herpesvirus 4 in captive asian elephants (Elephas maximus) in Thailand. Wetchasan sattawaphaet = The Thai journal of veterinary medicine. 2017. DOI: https://doi.org/10.56808/2985-1130.2817

[48] Seilern-Moy K, Bertelsen M, Leifsson P, Perrin K, Haycock J, Dastjerdi A. Fatal elephant endotheliotropic herpesvirus-1 and -4 co-infection in a juvenile Asian elephant in Europe. JMM Case Reports. 2016. DOI: https://doi.org/10.1099/JMMCR.0.005005

[49] Sittisak T, Guntawang T, Srivorakul S, Photichai K, Muenthaisong A, Rittipornlertrak A, et al.. Evaluation of the immunogenicity of elephant endotheliotropic herpesvirus glycoprotein B (EEHV-gB) subunit vaccines in a mouse model.. Acta Tropica. 2025. DOI: https://doi.org/10.1016/j.actatropica.2025.107571

[50] Guntawang T, Sittisak T, Tankaew P, Thitaram C, Langkapin V, Angkawanish T, et al.. Development of Nonstructural Protein-Based Indirect ELISA to Identify Elephant Endotheliotropic Herpesvirus (EEHV) Infection in Asian Elephants (Elephas maximus). Animals. 2022. DOI: https://doi.org/10.3390/ani12141747

[51] Guntawang T, Sittisak T, Srivorakul S, Kochagul V, Photichai K, Thitaram C, et al.. In vivo characterization of target cells for acute elephant endotheliotropic herpesvirus (EEHV) infection in Asian elephants (Elephas maximus). Scientific Reports. 2020. DOI: https://doi.org/10.1038/s41598-020-68413-4

[52] Photichai K, Guntawang T, Sittisak T, Kochagul V, Chuammitri P, Thitaram C, et al.. Attempt to Isolate Elephant Endotheliotropic Herpesvirus (EEHV) Using a Continuous Cell Culture System. Animals. 2020. DOI: https://doi.org/10.3390/ani10122328

[53] Srivorakul S, Guntawang T, Kochagul V, Photichai K, Sittisak T, Janyamethakul T, et al.. Possible roles of monocytes/macrophages in response to elephant endotheliotropic herpesvirus (EEHV) infections in Asian elephants (Elephas maximus). PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0222158

[54] Cook KA, Ling P, Terio K, Baumgartner W, Howard L, Landolfi J. DETECTION OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 1A IN ARCHIVAL TISSUE USING RNASCOPE® IN SITU HYBRIDIZATION. Journal of zoo and wildlife medicine. 2023. DOI: https://doi.org/10.1638/2022-0042

[55] Anderson KB, Steeil JC, Latimer EM, Hall V, Hayek L, Brandão J. CHANGES IN SERUM CARDIAC TROPONIN I IN ASIAN ELEPHANTS (ELEPHAS MAXIMUS) WITH ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS INFECTION. Journal of zoo and wildlife medicine. 2022. DOI: https://doi.org/10.1638/2021-0003

[56] Guntawang T, Sittisak T, Srivorakul S, Photichai K, Aiumurai P, Thitaram C, et al.. Development of an immunochromatographic strip test for antigen detection of elephant endotheliotropic herpesvirus in Asian elephants (Elephas maximus).. Journal of Virological Methods. 2022. DOI: https://doi.org/10.1016/j.jviromet.2022.114627

[57] Grenus BG, Latimer EM, Cullinane A, Lyons P, Creighton G, Nutter F. EVALUATION OF THE EFFICACY OF TWO DIFFERENT SAMPLING SITES FOR THE DETECTION OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS (EEHV) IN THREE ASIAN ELEPHANTS (ELEPHAS MAXIMUS) IN IRELAND. Journal of zoo and wildlife medicine. 2020. DOI: https://doi.org/10.1638/2018-0193

[58] Sylvester H, Raines J, Burgdorf-moisuk A, Connolly M, Wilson S, Ripple L, et al.. SELECTED INSTANCES OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS SHEDDING IN TRUNK SECRETIONS BY AFRICAN ELEPHANTS (LOXODONTA AFRICANA) IN COMPARISON TO SHEDDING BY ASIAN ELEPHANTS (ELEPHAS MAXIMUS). Journal of zoo and wildlife medicine. 2024. DOI: https://doi.org/10.1638/2022-0046

[59] Takehana K, Hoornweg T, Schaftenaar W, Rutten VP, Haan CAMd, Matsuno K. Elephant endotheliotropic herpesvirus gB-specific antibody levels in sera of Asian elephants (Elephas maximus) in Japanese zoos. Journal of Veterinary Medical Science. 2024. DOI: https://doi.org/10.1292/jvms.23-0503

[60] Kosaruk W, Brown JL, Towiboon P, Pringproa K, Punyapornwithaya V, Tankaew P, et al.. Seasonal patterns of oxidative stress markers in captive Asian elephants in Thailand and relationships to elephant endotheliotropic herpesvirus shedding. Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2023.1263775

[61] Edwards KL, Latimer EM, Siegal-Willott J, Kiso W, Padilla L, Sánchez CR, et al.. Patterns of serum immune biomarkers during elephant endotheliotropic herpesvirus viremia in Asian and African elephants. bioRxiv. 2021. DOI: https://doi.org/10.1371/journal.pone.0252175

[62] Common SM, Yun Y, Silva-Fletcher A, Thitaram C, Janyamethakul T, Khammesri S, et al.. Developing a non-invasive method of detecting elephant endotheliotropic herpesvirus infections using faecal samples.. The Veterinary Record. 2021. DOI: https://doi.org/10.1002/vetr.833

[63] Jeffrey A, Evans TS, Molter C, Howard L, Ling P, Goldstein T, et al.. NONINVASIVE SAMPLING FOR DETECTION OF ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS AND GENOMIC DNA IN ASIAN (ELEPHAS MAXIMUS) AND AFRICAN (LOXODONTA AFRICANA) ELEPHANTS. Journal of zoo and wildlife medicine. 2020. DOI: https://doi.org/10.1638/2019-0112

[64] Gani M, Karuppannan K, Razak MFA, Mohammed AA. Detection of subclinical EEHV infection in captive Asian elephants (Elephas maximus) in Peninsular Malaysia through a molecular approach. Veterinary Integrative Sciences. 2023. DOI: https://doi.org/10.12982/vis.2025.075

[65] Iyer ML, Molter C, Flanagan J, Bauer KL, Bernardy R, Hoffman D, et al.. NOVEL DIAGNOSTIC AND THERAPEUTIC APPROACHES TO ELEPHANT ENDOTHELIOTROPIC HERPESVIRUS 1A HEMORRHAGIC DISEASE IN A CAPTIVE JUVENILE ASIAN ELEPHANT (ELEPHAS MAXIMUS). Journal of zoo and wildlife medicine. 2022. DOI: https://doi.org/10.1638/2021-0096

[66] Khammesri S, Mathura Y, Boonprasert K, Ampasavate C, Hongwiset D, Brown JL, et al.. Successful treatment of elephant endotheliotropic herpesvirus infection in an Asian elephant (Elephas maximus) calf by oral acyclovir medication: Case report. Journal of Veterinary Medical Science. 2020. DOI: https://doi.org/10.1292/jvms.20-0375

[67] Takehana K, Matsuno K. Direct detection of elephant endotheliotropic herpesvirus 1 (EEHV1) DNA in heparinized plasma by loop-mediated isothermal amplification. Journal of Veterinary Medical Science. 2023. DOI: https://doi.org/10.1292/jvms.22-0578

[68] Haycock J, Maehr T, Dastjerdi A, Steinbach F. Immunostimulation of Asian elephant (Elephas maximus) blood cells by parapoxvirus ovis and CpG motif-containing bacterial plasmid DNA upregulates innate immune gene expression. Frontiers in Immunology. 2024. DOI: https://doi.org/10.3389/fimmu.2024.1329820

[69] Bauer KL, Latimer EM, Finnegan M. Long-term, intermittent, low-level elephant endotheliotropic herpesvirus 1A viremia in a captive Asian elephant calf. Journal of Veterinary Diagnostic Investigation. 2018. DOI: https://doi.org/10.1177/1040638718803138

[70] Kittisirikul N, Bangkaew N, Phimpraphai W, Sripiboon S. Unlocking insights: Mahout’s perceptions and practices in managing Elephant Endotheliotropic Herpesvirus (EEHV) infection among captive Asian elephants in Surin province, Thailand. PLoS ONE. 2024. DOI: https://doi.org/10.1371/journal.pone.0295869

[71] Sittisak T, Guntawang T, Srivorakul S, Photichai K, Boonprasert K, Khammesri S, et al.. Response of elephant peripheral blood mononuclear cells when stimulated with elephant endotheliotropic herpesvirus glycoprotein B (EEHV-gB).. Veterinary Immunology and Immunopathology. 2023. DOI: https://doi.org/10.1016/j.vetimm.2023.110577

[72] Thitaram C, Bansiddhi P, Pakamma A, Arintasai K, Khammesri S, Sirikul C, et al.. Long-term biochemical stability of fresh-frozen plasma from Asian elephants (Elephas maximus) stored at −20°C: Implications for emergency transfusion protocols for elephant endotheliotropic herpesvirus hemorrhagic disease. Veterinary World. 2026. DOI: https://doi.org/10.14202/vetworld.2026.125-134